Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2023

Commission File Number 001-33720

Remark Holdings, Inc.

Delaware

33-1135689

State of Incorporation

IRS Employer Identification Number

800 S. Commerce St.

Las Vegas, NV 89106

Address, including zip code, of principal executive offices

702-701-9514

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.001 par value per share

MARK

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☑

Smaller reporting company

☑

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of November 17, 2023, a total of 20,931,855 shares of the issuer’s common stock were outstanding.

TABLE OF CONTENTS


PART I
Item 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets at September 30, 2023 (unaudited) and December 31, 2022	1
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023	2
	Unaudited Condensed Consolidated Statements of Stockholders’ Deficit for the three and nine months ended September 30, 2023	3
	Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023	4
	Notes to Unaudited Condensed Consolidated Financial Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
Item 4.	Controls and Procedures	39

PART II
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	42
Item 3.	Defaults Upon Senior Securities	42
Item 4.	Mine Safety Disclosures	42
Item 5.	Other Information	42
Item 6.	Exhibits	43
	Signature	45


Table of Contents			i

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The following information should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (this “Form 10-Q”) and our audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023 (the “2022 Form 10-K”).

In addition to historical information, this Form 10-Q includes “forward-looking statements” about the plans, strategies, objectives, goals or expectations of Remark Holdings, Inc. and subsidiaries (“Remark”, “we”, “us”, “our”). You will find forward-looking statements principally in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Such forward-looking statements are identifiable by words or phrases indicating that Remark or management “expects,” “anticipates,” “plans,” “believes,” or “estimates,” or that a particular occurrence or event “will,” “may,” “could,” “should,” or “will likely” result, occur or be pursued or “continue” in the future, that the “outlook” or “trend” is toward a particular result or occurrence, that a development is an “opportunity,” “priority,” “strategy,” “focus,” that we are “positioned” for a particular result, or similarly-stated expectations. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this report or such other report, release, presentation, or statement. The forward-looking statements contained in this Form 10-Q are based on the expectations, estimates, projections, beliefs, and assumptions of our management based on information available to management as of the date on which this Form 10-Q was filed with the SEC, or as of the date on which the information incorporated by reference was filed with the SEC, as applicable, all of which are subject to change. Forward-looking statements are subject to risks, uncertainties, and other factors that are difficult to predict and could cause actual results to differ materially from those stated or implied by our forward-looking statements.

In addition to other risks and uncertainties described in connection with the forward-looking statements contained in this report and other periodic reports filed with the SEC, there are many important factors that could cause actual results to differ materially. Such risks and uncertainties include general business conditions, changes in overall economic conditions, our ability to integrate acquired assets, the impact of competition and other factors which are often beyond our control.

This should not be construed as a complete list of all of the economic, competitive, governmental, technological and other factors that could adversely affect our expected consolidated financial position, results of operations or liquidity. Additional risks and uncertainties not currently known to us or that we currently believe are immaterial also may impair our business, operations, liquidity, financial condition and prospects. We undertake no obligation to update or revise our forward-looking statements to reflect developments that occur or information that we obtain after the date of this report.


Table of Contents			ii

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

REMARK HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(dollars in thousands, except share and per share amounts)




	September 30, 2023		December 31, 2022
	(Unaudited)
Assets
Cash	$	270	$	52
Trade accounts receivable, net	3,043		3,091
Inventory, net	455		308

Deferred cost of revenue	5,899		7,463
Prepaid expense and other current assets	801		1,374
Total current assets	10,468		12,288
Property and equipment, net	1,106		1,699
Operating lease assets	678		180
Other long-term assets	146		269
Total assets	$	12,398	$	14,436
Liabilities
Accounts payable	$	8,578	$	9,602
Advances from related parties	1,030		1,174
Obligations to issue common stock	9,184		1,892
Accrued expense and other current liabilities	9,353		7,222
Contract liability	363		308
Notes payable (past due)	16,472		14,607
Total current liabilities	44,980		34,805

Operating lease liabilities, long-term	336		56


Total liabilities	45,316		34,861

Commitments and contingencies

Stockholders’ Deficit
Preferred stock, $0.001 par value; 1,000,000 shares authorized; zero issued	—		—
Common stock, $0.001 par value; 175,000,000 shares authorized; 19,711,855 and 11,539,564 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	20		12
Additional paid-in-capital	378,022		368,945
Accumulated other comprehensive loss	(1,229)		(859)
Accumulated deficit	(409,731)		(388,523)
Total stockholders’ deficit	(32,918)		(20,425)
Total liabilities and stockholders’ deficit	$	12,398	$	14,436

See Notes to Unaudited Condensed Consolidated Financial Statements


Table of Contents			1

REMARK HOLDINGS, INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(dollars in thousands, except per share amounts)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Revenue, including amounts from China Business Partner (See Note 15)	$	183	$	2,812	$	4,176	$	10,037
Cost and expense
Cost of revenue (excluding depreciation and amortization)	254		2,459		3,220		8,576
Sales and marketing	340		270		1,093		606
Technology and development	768		41		1,504		1,004
General and administrative	2,843		6,726		8,920		14,598
Depreciation and amortization	107		43		178		121
Impairments	—		—		392		—

Total cost and expense	4,312		9,539		15,307		24,905
Operating loss	(4,129)		(6,727)		(11,131)		(14,868)
Other income (expense)
Interest expense	(949)		(1,365)		(3,351)		(5,325)
Finance cost related to obligations to issue common stock	(2,086)		—		(6,712)		—

Loss on investment	—		(348)		—		(26,356)
Other gain, net	(8)		(493)		(14)		(342)
Total other expense, net	(3,043)		(2,206)		(10,077)		(32,023)
Loss before income taxes	(7,172)		(8,933)		(21,208)		(46,891)
Provision for income taxes	—		9		—		9
Net loss	$	(7,172)	$	(8,924)	$	(21,208)	$	(46,882)
Other comprehensive income
Foreign currency translation adjustments	175		(445)		(370)		(867)
Comprehensive loss	$	(6,997)	$	(9,369)	$	(21,578)	$	(47,749)

Weighted-average shares outstanding, basic and diluted	18,377,384		10,529,055		15,355,583		10,529,055


Net loss per share, basic and diluted	$	(0.39)	$	(0.85)	$	(1.38)	$	(4.45)

See Notes to Unaudited Condensed Consolidated Financial Statements


Table of Contents			2			Financial Statement Index

REMARK HOLDINGS, INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Stockholders’ Deficit

(in thousands, except number of shares)


	Three Months Ended September 30, 2023
	Common Stock Shares	Common Stock Par Value		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total
Balance at June 30, 2023	16,612,266	$	17	$	375,517	$	(1,404)	$	(402,559)	(28,429)
Net loss	—	—		—		—		(7,172)		(7,172)
Share-based compensation	—	—		11		—		—		11
Common stock issued pursuant to agreements with Ionic (Note 11)	3,099,589	3		2,494		—		—		2,497

Foreign currency translation	—	—		—		175		—		175
Balance at September 30, 2023	19,711,855	$	20	$	378,022	$	(1,229)	$	(409,731)	$	(32,918)

	Three Months Ended September 30, 2022
	Common Stock Shares	Common Stock Par Value		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total
Balance at June 30, 2022	10,515,777	$	11	$	365,357	$	(692)	$	(370,998)	$	(6,322)
Net loss	—	—		—		—		(8,924)		(8,924)
Share-based compensation	—	—		501		—		—		501
Common stock issued for services	125,000	1		499		—		—		500




Foreign currency translation	—	—		—		(445)		—		(445)

Balance at September 30, 2022	10,640,777	$	12	$	366,357	$	(1,137)	$	(379,922)	$	(14,690)

	Nine Months Ended September 30, 2023
	Common Stock Shares	Common Stock Par Value		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total
Balance at December 31, 2022	11,539,564	$	12	$	368,945	$	(859)	$	(388,523)	$	(20,425)
Net loss	—	—		—		—		(21,208)		(21,208)
Share-based compensation	—	—		167		—		—		167
Common stock issued pursuant to agreements with Ionic (Note 11)	8,172,291	8		8,910		—		—		8,918

Foreign currency translation	—	—		—		(370)		—		(370)
Balance at September 30, 2023	19,711,855	$	20	$	378,022	$	(1,229)	$	(409,731)	$	(32,918)

	Nine Months Ended September 30, 2022
	Common Stock Shares	Common Stock Par Value		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total
Balance at December 31, 2021	10,515,777	$	11	$	364,333	$	(270)	$	(333,040)	$	31,034
Net loss	—	—		—		—		(46,882)		(46,882)
Share-based compensation	—	—		1,525		—		—		1,525
Common stock issued for services	125,000	1		499		—		—		500




Foreign currency translation	—	—		—		(867)		—		(867)

Balance at September 30, 2022	10,640,777	$	12	$	366,357	$	(1,137)	$	(379,922)	$	(14,690)

See Notes to Unaudited Condensed Consolidated Financial Statements


Table of Contents			3			Financial Statement Index

REMARK HOLDINGS, INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Cash Flows

(dollars in thousands)


	Nine Months Ended September 30,
	2023		2022
Cash flows from operating activities:
Net loss	$	(21,208)	$	(46,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	178		121
Share-based compensation	149		1,185
Amortization of debt issuance costs and discount	—		2,189
Cost of extending note payable	750		—
Finance cost related to obligations to issue common stock	6,712		—
Accrued interest included in note payable	1,139		283
Stock issuance for services performed	—		500
Loss on investment	—		26,356
Impairment of assets	392		—
Provision for doubtful accounts	138		2,278
Other	224		(178)
Changes in operating assets and liabilities:
Accounts receivable	(593)		1,298
Inventory	83		(209)
Deferred cost of revenue	1,564		(5,041)
Prepaid expense and other assets	85		3,815
Operating lease assets	(503)		63
Accounts payable, accrued expense and other liabilities	1,437		826
Contract liability	90		(245)
Operating lease liabilities	280		6
Net cash used in operating activities	(9,083)		(13,635)
Cash flows from investing activities:
Proceeds from sale of investment	—		6,332
Purchases of property, equipment and software	(32)		(175)
Payment of amounts capitalized to software in progress	—		(999)
Net cash provided by (used in) investing activities	(32)		5,158
Cash flows from financing activities:
Proceeds from issuance of common stock, net	—		—
Proceeds from obligations to issue common stock - ELOC	7,000		—
Proceeds from obligations to issue common stock - Debentures	2,500		—
Advances from related parties	1,002		2,386
Repayments of advances from related parties	(1,145)		(1,517)
Repayments of debt	(24)		(6,203)
Net cash provided by (used in) financing activities	9,333		(5,334)
Net change in cash	218		(13,811)
Cash:
Beginning of period	52		14,187
End of period	$	270	$	376

Supplemental cash flow information:
Cash paid for interest	$	1,578	$	3,238

Supplemental schedule of non-cash investing and financing activities:
Transfer of marketable securities to partially settle notes payable	$	—	$	9,661
Finance fee	$	—	$	283
Issuance of common stock pursuant to equity line of credit	$	8,910	$	—
Transfer of software to inventory	$	233	$	—

See Notes to Unaudited Condensed Consolidated Financial Statements


Table of Contents			4			Financial Statement Index

REMARK HOLDINGS, INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements

For the Nine Months Ended September 30, 2023 and 2022

NOTE 1. ORGANIZATION AND BUSINESS

Organization and Business

Remark Holdings, Inc. and its subsidiaries (“Remark”, “we”, “us”, or “our”) constitute a diversified global technology business with leading artificial intelligence (“AI”) and data-analytics solutions. The common stock of Remark Holdings, Inc. is listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol MARK.

We primarily sell AI-based products and services. We currently recognize substantially all of our revenue from China, with additional revenue from sales in the U.S.

On December 21, 2022, we effected a 1-for-10 reverse split of our common stock (the “Reverse Split”). All references made to share or per share amounts in these financial statements have been retroactively adjusted to reflect the effects of the Reverse Split.

Corporate Structure

We are a holding company incorporated in Delaware and not a Chinese operating company. As a holding company, we conduct most of our operations through our subsidiaries, each of which is wholly owned. Until September 2022, we had historically conducted a significant part of our operations through contractual arrangements between our wholly-foreign-owned enterprise (“WFOE”) and certain variable interest entities (“VIEs”) based in China to address challenges resulting from laws, policies and practices that may disfavor foreign-owned entities that operate within industries deemed sensitive by the Chinese government. We were the primary beneficiary of the VIEs because the contractual arrangements governing the relationship between the VIEs and our WFOE, which included an exclusive call option agreement, exclusive business cooperation agreement, a proxy agreement and an equity pledge agreement, enabled us to (i) exercise effective control over the VIEs, (ii) receive substantially all of the economic benefits of the VIEs, and (iii) have an exclusive call option to purchase, at any time, all or part of the equity interests in and/or assets of the VIEs to the extent permitted by Chinese laws. Because we were the primary beneficiary of the VIEs, we consolidated the financial results of the VIEs in our consolidated financial statements in accordance with generally accepted accounting principles (“GAAP”).

We terminated all of the contractual arrangements between the WFOE and the VIEs and exercised our rights under the exclusive call option agreements between the WFOE and the VIEs such that, effective as of September 19, 2022, we obtained 100% of the equity ownership of the entities we formerly consolidated as VIEs and which we now consolidate as wholly-owned subsidiaries.

The following diagram illustrates our corporate structure, including our significant subsidiaries, as of the date of this Form 10-Q. The diagram omits certain entities which are immaterial to our results of operations and financial condition.


Table of Contents			5			Financial Statement Index

We are subject to certain legal and operational risks associated with having a significant portion of our operations in China. Chinese laws and regulations governing our current business operations, including the enforcement of such laws and regulations, are sometimes vague and uncertain and can change quickly with little advance notice. The Chinese government may intervene in or influence the operations of our China-based subsidiaries at any time and may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value of our securities. In addition, any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer our securities to investors and cause the value of such securities to


Table of Contents			6			Financial Statement Index

significantly decline or become worthless. In recent years, the Chinese government adopted a series of regulatory actions and issued statements to regulate business operations in China, including those related to the use of variable interest entities, cybersecurity, data security, export control and anti-monopoly concerns. As of the date of this Form 10-Q, we have neither been involved in any investigations on cybersecurity review initiated by any Chinese regulatory authority, nor received any inquiry, notice or sanction. As of the date of this Form 10-Q, no relevant laws or regulations in China explicitly require us to seek approval from the China Securities Regulatory Commission (“CSRC”) for any securities listing. As of the date of this Form 10-Q, we have not received any inquiry, notice, warning or sanctions regarding our planned overseas listing from the CSRC or any other Chinese governmental authorities relating to securities listings. However, since these statements and regulatory actions are newly published, official guidance and related implementation rules have not all been issued. It is highly uncertain what potential impact such modified or new laws and regulations will have on our ability to conduct our business, accept investments or list or maintain a listing on a U.S. or foreign exchange.

As of the date of this Form 10-Q, we are not required to seek permissions from the CSRC, the Cyberspace Administration of China (the “CAC”), or any other entity that is required to approve our operations in China. Nevertheless, Chinese regulatory authorities may in the future promulgate laws, regulations or implement rules that require us or our subsidiaries to obtain permissions from such regulatory authorities to approve our operations or any securities listing.

Holding Foreign Companies Accountable Act

The Holding Foreign Companies Accountable Act (the “HFCA Act”) was enacted on December 18, 2020. The HFCA Act states that if the Securities and Exchange Commission (the “SEC”) determines that a company has filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the Public Company Accounting Oversight Board (the “PCAOB”) for three consecutive years beginning in 2021, the SEC shall prohibit such shares from being traded on a national securities exchange or in the over the counter trading market in the United States. On December 2, 2021, the SEC adopted amendments to finalize rules implementing the submission and disclosure requirements in the HFCA Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB is unable to inspect or investigate completely because of a position taken by an authority in a foreign jurisdiction. The Consolidated Appropriations Act, 2023, which was signed into law on December 29, 2022, amended the HFCA Act to reduce the number of consecutive non-inspection years required to trigger the trading prohibition under the HFCA Act from three years to two years.

On December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and in Hong Kong because of positions taken by Chinese and Hong Kong authorities in those jurisdictions.

On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol (the “Protocol”), taking the first step toward opening access for the PCAOB to completely inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong.

On December 15, 2022, the PCAOB vacated its 2021 determination that the positions taken by authorities in mainland China and Hong Kong prevented it from inspecting and investigating completely registered public accounting firms headquartered in those jurisdictions. In view of the PCAOB’s decision to vacate its 2021 determination and until such time as the PCAOB issues any new adverse determination, the SEC has stated that there are no issuers at risk of having their securities subject to a trading prohibition under the HFCA Act. Each year, the PCAOB will reassess its determinations on whether it can inspect and investigate completely audit firms in China, and if, in the future, the PCAOB determines it cannot do so, or if Chinese authorities do not allow the PCAOB complete access for inspections and investigations for two consecutive years, companies engaging China-based public accounting firms would be delisted pursuant to the HFCA Act.

Our auditor, Weinberg & Company, an independent registered public accounting firm headquartered in the United States is currently subject to PCAOB inspections and has been inspected by the PCAOB on a regular basis. However, if the PCAOB is unable to inspect the work papers of our accounting firm in the future, such lack of inspection could cause trading in our common stock to be prohibited under the HFCA Act, and as a result, an exchange may determine to delist our common stock. The delisting and the cessation of trading of our common stock, or the threat of our common stock being delisted and prohibited from being traded, may materially and adversely affect the value of our common stock.


Table of Contents			7			Financial Statement Index

Transfer of Cash or Assets

Dividend Distributions

As of the date of this Form 10-Q, none of our subsidiaries have made any dividends or distributions to Remark.

We have never declared or paid dividends or distributions on our common equity. We currently intend to retain all available funds and any future consolidated earnings to fund our operations and continue the development and growth of our business; therefore, we do not anticipate paying any cash dividends.

Under Delaware law, a Delaware corporation’s ability to pay cash dividends on its capital stock requires the corporation to have either net profits or positive net assets (total assets less total liabilities) over its capital. If we determine to pay dividends on any of our common stock in the future, as a holding company, we may rely on dividends and other distributions on equity from our subsidiaries for cash requirements, including the funds necessary to pay dividends and other cash contributions to our stockholders.

Our WFOE’s ability to distribute dividends is based upon its distributable earnings. Current Chinese regulations permit our WFOE to pay dividends to its shareholder only out of its registered capital amount, if any, as determined in accordance with Chinese accounting standards and regulations, and then only after meeting the requirement regarding statutory reserve. If our WFOE incurs debt in the future, the instruments governing the debt may restrict its ability to pay dividends or make other payments to us. Any limitation on the ability of our WFOE to distribute dividends or other payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our businesses, pay dividends or otherwise fund and conduct our business. In addition, any cash dividends or distributions of assets by our WFOE to its stockholder are subject to a Chinese withholding tax of as much as 10%.

The Chinese government also imposes controls on the conversion of Chinese Renminbi (“RMB”) into foreign currencies and the remittance of currencies out of China. Therefore, we may experience difficulties in completing the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from our profits, if any. If we are unable to receive all of the revenues from our operations through our China-based subsidiaries, we may be unable to pay dividends on our common stock.

COVID-19

Our condensed consolidated financial statements for the nine months ended September 30, 2023 continued to show the negative impact that the COVID-19 pandemic has had on our business. Preventative measures related to COVID-19 outbreaks may continue to adversely affect our business and financial results, as could economic and geopolitical conditions in some international regions, and we do not yet know what will be the ultimate effects on our business. The COVID-19 pandemic caused a broad shift towards remote working arrangements for many businesses worldwide and injected uncertainty and delay into decision-making processes for such businesses. Though the most restrictive preventative measures have been eased in China, city-wide lockdowns, travel restrictions, closures of non-essential businesses and other quarantine measures could be reinstituted at any time. Recovering from the effects of the preventative measures in China that resulted from the Chinese government’s Zero-COVID policy and that significantly limited the operational capabilities of our China-based subsidiaries has been a slow process. Though the weeks-long or months-long lockdowns instituted in many cities across large swaths of China, including economically significant regions such as Shanghai, were lifted as of the end of 2022, they have had a material adverse impact on our business, including on the collection of our accounts receivable and our ability to complete projects in China to generate revenue, and may continue to adversely impact our business until customers and potential customers believe they can operate and expand their businesses without fear of lockdowns or other severely restrictive preventative measures.

The full extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including resurgences and further spread of existing or new COVID-19 variants, the duration of any remaining preventative measures implemented by domestic and foreign governments, the impact on capital and financial markets and the related impact on the financial circumstances of our customers, all of which are highly uncertain and cannot be predicted. The COVID-19 situation has historically changed rapidly, and additional impacts of which we are not currently aware may arise. We are closely monitoring worldwide developments and continually assess the potential impact on our business.


Table of Contents			8			Financial Statement Index

Going Concern

During the nine months ended September 30, 2023, and in each fiscal year since our inception, we have incurred operating losses which have resulted in a stockholders’ deficit of $32.9 million as of September 30, 2023. Additionally, our operations have historically used more cash than they have provided. Net cash used in operating activities was $9.1 million during the nine months ended September 30, 2023. As of September 30, 2023, our cash balance was $0.3 million. Also, we did not make required repayments of the outstanding loans under the New Mudrick Loan Agreement when due (see Note 10 for more information).

Our history of recurring operating losses, working capital deficiencies and negative cash flows from operating activities give rise to, and management has concluded that there is, substantial doubt regarding our ability to continue as a going concern. Our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December 31, 2022, has also expressed substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We intend to fund our future operations and meet our financial obligations through revenue growth from our AI and data analytics offerings. We cannot, however, provide assurance that revenue, income and cash flows generated from our businesses will be sufficient to sustain our operations in the twelve months following the filing of this Form 10-Q. As a result, we are actively evaluating strategic alternatives including debt and equity financings.

Conditions in the debt and equity markets, as well as the volatility of investor sentiment regarding macroeconomic and microeconomic conditions (in particular, as a result of the COVID-19 pandemic, global supply chain disruptions, inflation and other cost increases, and the geopolitical conflict in Ukraine), will play primary roles in determining whether we can successfully obtain additional capital. We cannot be certain that we will be successful at raising additional capital.

A variety of factors, many of which are outside of our control, affect our cash flow; those factors include the effects of the COVID-19 pandemic, regulatory issues, competition, financial markets and other general business conditions. Based on financial projections, we believe that we will be able to meet our ongoing requirements for at least the next 12 months with existing cash and based on the probable success of one or more of the following plans:

•develop and grow new product line(s)

•obtain additional capital through debt and/or equity issuances.

However, projections are inherently uncertain and the success of our plans is largely outside of our control. As a result, there is substantial doubt regarding our ability to continue as a going concern, and we may fully utilize our cash resources prior to December 31, 2023.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

We prepared the accompanying unaudited Condensed Consolidated Balance Sheet as of September 30, 2023, with the audited Consolidated Balance Sheet amounts as of December 31, 2022 presented for comparative purposes, and the related unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss, the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Deficit nine months ended September 30, 2023 in accordance with the instructions for Form 10-Q. In compliance with those instructions, we have omitted certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP, though management believes the disclosures made herein are sufficient to ensure that the information presented is not misleading.

Our results of operations and our cash flows as of the end of the interim periods reported herein do not necessarily indicate the results we may experience for the remainder of the year or for any other future period.

Management believes that we have included all adjustments (including those of a normal, recurring nature) considered necessary to fairly present our unaudited Condensed Consolidated Balance Sheet and our unaudited Condensed Consolidated


Table of Contents			9			Financial Statement Index

Statement of Stockholders’ Deficit, each as of September 30, 2023, as well as our unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss and Condensed Consolidated Statements of Cash Flows for all periods presented. You should read our unaudited condensed consolidated interim financial statements and footnotes in conjunction with our consolidated financial statements and footnotes included within the Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).

Consolidation

We include all of our subsidiaries in our condensed consolidated financial statements, eliminating all significant intercompany balances and transactions during consolidation.

Use of Estimates

We prepare our consolidated financial statements in conformity with GAAP. While preparing our financial statements, we make estimates and assumptions that affect amounts reported and disclosed in the consolidated financial statements and accompanying notes. Accordingly, actual results could differ from those estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, deferred cost of revenue, share-based compensation, deferred income taxes, and inventory reserve, among other items.

The impact of the COVID-19 pandemic continues to unfold. As a result, many of our estimates and assumptions required increased judgment and carry a higher degree of variability and volatility. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.

Cash

Our cash consists of funds held in bank accounts.

We maintain cash balances in United States dollars (“USD”), British pounds (“GBP”), RMB and Hong Kong dollars (“HKD”). The following table, reported in USD, disaggregates our cash balances by currency denomination (in thousands):




	September 30, 2023		December 31, 2022
Cash denominated in:
USD	$	250	$	11
RMB	13		19
GBP	3		17
HKD	4		5
Total cash	$	270	$	52

We maintain substantially all of our USD-denominated cash at a U.S. financial institution where the balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At times, however, our cash balances may exceed the FDIC-insured limit. As of September 30, 2023, we do not believe we have any significant concentrations of credit risk. Cash held by our non-U.S. subsidiaries is subject to foreign currency fluctuations against the USD, although such risk is somewhat mitigated because we transfer U.S. funds to China to fund local operations. If, however, the USD is devalued significantly against the RMB, our cost to further develop our business in China could exceed original estimates.


Table of Contents			10			Financial Statement Index

Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). When reporting the fair values of our financial instruments, we prioritize those fair value measurements into one of three levels based on the nature of the inputs, as follows:

Level 1: Valuations based on quoted prices in active markets for identical assets and liabilities;

Level 2: Valuations based on observable inputs that do not meet the criteria for Level 1, including quoted prices in inactive markets and observable market data for similar, but not identical instruments; and

Level 3: Valuations based on unobservable inputs, which are based upon the best available information when external market data is limited or unavailable.

The fair value hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not be available.

We believe the reported carrying amounts for cash, marketable securities, receivables, prepaids and other current assets, accounts payable, accrued expense and other current liabilities, and short-term debt approximate their fair values because of the short-term nature of these financial instruments.

Foreign Currency Translation

We report all currency amounts in USD. Our overseas subsidiaries, however, maintain their books and records in their functional currencies, which are GBP in the United Kingdom (“U.K.”) and RMB in China.

In general, when consolidating our subsidiaries with non-USD functional currencies, we translate the amounts of assets and liabilities into USD using the exchange rate on the balance sheet date, and the amounts of revenue and expense are translated at the average exchange rate prevailing during the period. The gains and losses resulting from translation of financial statement amounts into USD are recorded as a separate component of accumulated other comprehensive loss within stockholders’ deficit.

We used the exchange rates in the following table to translate amounts denominated in non-USD currencies as of and for the periods noted:


	2023	2022
Exchange rates at September 30th:
GBP:USD	1.220	1.113
RMB:USD	0.137	0.141
HKD:USD	0.128	0.127

Average exchange rate during the nine months ended September 30th:
RMB:USD	0.142	0.152
GBP:USD	1.244	1.259


Table of Contents			11			Financial Statement Index

Revenue Recognition

AI-Based Products

We generate revenue by developing AI-based products, including fully-integrated AI solutions which combine our proprietary technology with third-party hardware and software products to meet end-user specifications. Under one type of contract for our AI-based products, we provide a single, continuous service to clients who control the assets as we create them. Accordingly, we recognize the revenue over the period of time during which we provide the service. Under another type of contract, we have performance obligations to provide fully-integrated AI solutions to our customer and we recognize revenue at the point in time when each performance obligation is completed and delivered to, tested by and accepted by our customer.

We recognize revenue when we transfer control of the promised goods or services to our customers, and we recognize an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. If there is uncertainty related to the timing of collections from our customer, which may be the case if our customer is not the ultimate end user of our goods, we consider this to be uncertainty of the customer’s ability and intention to pay us when consideration is due. Accordingly, we recognize revenue only when we have transferred control of the goods or services and collectability of consideration from the customer is probable.

When customers pay us prior to when we satisfy our obligation to transfer control of promised goods or services, we record the amount that reflects the consideration to which we expect to be entitled as a contract liability until such time as we satisfy our performance obligation.

For contracts under which we have not yet completed the performance obligation, deferred costs are recorded for any amounts incurred in advance of the performance obligation.

For our contracts with customers, we generally extend short-term credit policies to our customers, typically up to one year for large-scale projects.

We record the incremental costs of obtaining contracts as an expense when incurred.

We offer extended warranties on our products for periods of one to three years. Revenue from these extended warranties is recognized on a straight-line basis over the warranty contract term.

Other

We generate revenue from other sources, such as from advertising and marketing services. We recognize the revenue from these contracts at the point in time when we transfer control of the good sold to the customer or when we deliver the promised promotional materials or media content. Substantially all of our contracts with customers that generate Other revenue are completed within one year or less.


Table of Contents			12			Financial Statement Index

Inventory

We use the first-in first-out method to determine the cost of our inventory, then we report inventory at the lower of cost or net realizable value. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated sales forecasts. At September 30, 2023 and December 31, 2022, reserve for inventory was $2.2 million and $2.2 million, respectively.

Refundable Tax Credits

We charge the cost of our research and development efforts to operations as incurred. Our subsidiary in the United Kingdom is entitled to receive certain government assistance in the form of refundable research and development tax credits from taxation authorities, based on qualifying expenditures incurred during the fiscal year. The refundable credits are not dependent on our ongoing tax status or tax position and accordingly are not considered part of income taxes. We record refundable tax credits as a reduction of technology and development expense when we can reasonably estimate the amount and it is more likely than not that such amount will be received. During the nine months ended September 30, 2023, we recorded a tax credit of approximately $0.5 million.

Internal Use Software

We acquire or develop applications and other software that help us meet our internal needs with respect to operating our business. For such projects, planning cost and other costs related to the preliminary project stage, as well as costs incurred for post-implementation activities, are expensed as incurred. We capitalize costs incurred during the application development phase only when we believe it is probable the development will result in new or additional functionality. The types of costs capitalized during the application development phase include fees incurred with third parties for consulting, programming and other development activities performed to complete the software. We amortize our internal use software on a straight-line basis over an estimated useful life of three years. If we identify any internal use software to be abandoned, the cost less the accumulated amortization, if any, is recorded as amortization expense. Once we have fully amortized internal use software costs that we capitalized, we remove such amounts from their respective accounts.

Net Income (Loss) per Share

We calculate basic net income (loss) per share using the weighted-average number of common stock shares outstanding during the period. For the calculation of diluted net income (loss) per share, we give effect to all the shares of common stock that were outstanding during the period plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is anti-dilutive. Dilutive potential shares of common stock consist of incremental shares of common stock issuable upon exercise of stock options and warrants.

For the three and nine months ended September 30, 2023 and 2022, there were no reconciling items related to either the numerator or denominator of the loss per share calculation, as their effect would have been anti-dilutive.

Securities which may have affected the calculation of diluted earnings per share for the three and nine months ended September 30, 2023 if their effect had been dilutive include 1,623,346 total outstanding options to purchase our common stock, 1,011,441 outstanding warrants to purchase our common stock, as well as an estimated 18,420,287 shares of our common stock issuable to Ionic Ventures, LLC (“Ionic”) in relation to our transactions with Ionic (see Note 11).

Segments

Existing GAAP, which establishes a management approach to segment reporting, defines operating segments as components of an entity about which separate, discrete financial information is available for evaluation by the chief operating decision maker. We have identified our Chief Executive Officer as our chief operating decision maker, who reviews operating results to make decisions about allocating resources and assessing performance based upon only one operating segment.


Table of Contents			13			Financial Statement Index

Recently Issued Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06 (“ASU 2020-06”), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The ASU also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. With regard to our financial reporting, ASU 2020-06 will be effective January 1, 2024, and early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. We are currently evaluating what effect(s) the adoption of ASU 2020-06 may have on our consolidated financial statements, but we do not believe the impact of the ASU will be material to our financial position, results of operations and cash flows. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption.

We have reviewed all accounting pronouncements recently issued by the FASB and the SEC. The authoritative pronouncements that we have already adopted did not have a material effect on our financial condition, results of operations, cash flows or reporting thereof, and except as otherwise noted above, we do not believe that any of the authoritative pronouncements that we have not yet adopted will have a material effect upon our financial condition, results of operations, cash flows or reporting thereof.

NOTE 3. CONCENTRATION OF RISK

Revenue and Accounts Receivable

The disaggregation of revenue tables in Note 4 demonstrate the concentration in our revenue from certain products and the geographic concentration of our business. We also have a concentration in the volume of business we transacted with customers, as during the nine months ended September 30, 2023, two of our customers represented about 28% and 24% of our revenue, respectively, while during nine months ended September 30, 2022, two customers represented about 55% and 23%, respectively, of our revenue. At September 30, 2023, accounts receivable from two of our customers represented about 12% an 12%, respectively, of our gross accounts receivable, while at December 31, 2022, accounts receivable from our three largest customers represented about 23%, 16% and 10%, respectively, of our gross accounts receivable.

Deferred Cost of Revenue

See Note 6 for a discussion of a risk concentration regarding our deferred cost of revenue.

Cost of Sales and Accounts Payable

The various hardware we purchase to fulfill our contracts with customers is not especially unique in nature. Based on our analysis, we believe that should any disruption in our current supply chain occur, a sufficient number of alternative vendors is available to us, at reasonably comparable specifications and price, such that we would not experience a material negative impact on our ability to procure the hardware we need to operate our business.

NOTE 4. REVENUE

We primarily sell AI-based products and services based upon computer vision and other technologies.


Table of Contents			14			Financial Statement Index

We do not include disclosures related to remaining performance obligations because substantially all our contracts with customers have an original expected duration of one year or less or, with regard to our stand-ready obligations, the amounts involved are not material.

Disaggregation of Revenue

The following table presents a disaggregation of our revenue by category of products and services (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
AI-based products and services, including amounts from China Business Partner in 2023 (See Note 15)	$	174	$	2,681	$	4,000	$	9,699
Other	9		131		176		338
Revenue	$	183	$	2,812	$	4,176	$	10,037

The following table presents a disaggregation of our revenue by country (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
China	$	174	$	2,746	$	4,014	$	9,815
United States and United Kingdom	9		66		162		222

Revenue	$	183	$	2,812	$	4,176	$	10,037

Significant Judgments

When accounting for revenue we make certain judgments, such as whether we act as a principal or as an agent in transactions or whether our contracts with customers fall within the scope of current GAAP regarding revenue, that affect the determination of the amount and timing of our revenue from contracts with customers. Based on the current facts and circumstances related to our contracts with customers, none of the judgments we make involve an elevated degree of qualitative significance or complexity such that further disclosure is warranted in terms of their potential impact on the amount and timing of our revenue.

Contract Assets and Contract Liabilities

We do not currently generate material contract assets. During the nine months ended September 30, 2023, our contract liability changed only as a result of routine business activity.

During the nine months ended September 30, 2023 and 2022, the amount of revenue we recognized that was included in the beginning balance of Contract liability was not material.

During the nine months ended September 30, 2023 and 2022, we did not recognize revenue from performance obligations that were satisfied in previous periods.

Certain Agreements Related to AI-Based Product Sales in China

We completed certain projects in China during the three months ended September 30, 2023 worth approximately $1.4 million, but the agreement has not yet met the criteria for revenue recognition.


Table of Contents			15			Financial Statement Index

NOTE 5. TRADE ACCOUNTS RECEIVABLE




	September 30, 2023		December 31, 2022
Gross accounts receivable balance	$	7,103	$	7,213
Allowance for bad debt	(4,060)		(4,122)
Accounts receivable, net	$	3,043	$	3,091

Generally, it is not unusual for Chinese entities to pay their vendors on longer timelines than the timelines typically observed in U.S. commerce. Trade receivables related to our China AI projects at September 30, 2023 and December 31, 2022; including approximately $0.6 million and $1.1 million, respectively, of trade receivables from projects related to work with our China Business Partner (see Note 15 for more information regarding our China Business Partner and related accounting); represented essentially all our gross trade receivables in each such period. Despite the longer collection timelines normally observed with Chinese entities, we have noted that the COVID-19 related lockdowns that persisted in China for most of 2022 have caused further delay in our ability to collect all balances due from some of our customers in China. As a result of our inability to assure collection of all amounts due from such customers within a short period of time, we recorded a reserve for bad debt of approximately $2.8 million as of December 31, 2022 for all accounts receivable from China customers that were more than one year past due. The additional reserve for bad debt we recorded during 2023 was not material.

NOTE 6. DEFERRED COST OF REVENUE

Deferred cost of revenue as of September 30, 2023 and December 31, 2022 of $5.9 million and $7.5 million, respectively, represent amounts we have paid in advance to vendors who provide services to us in relation to various projects in China. Specifically, the deferred cost of revenue balance as of September 30, 2023, a large percentage of which was related to project installations we expected would be provided to us through our China Business Partner (described in more detail in Note 15), was paid almost entirely to a single vendor which will be visiting numerous sites across various regions of China to install our software solutions and/or hardware for our customers and perform other services for us pursuant to our customers’ requirements. Because most of the projects for which we have engaged the vendor require purchases of hardware, equipment and/or supplies in advance of site visits, we made the prepayments during 2022 in anticipation of several large batches of project installations. However, the lengthy COVID-19 related lockdowns that occurred in various regions in China prevented us and the vendor from being able to complete as many projects as we originally expected and caused our customers to delay installations. Given that the delays were related to the COVID-19 lockdowns that had ended by December 31, 2022 and were not a result of the vendor’s inability to either perform the services or refund of the amounts we advanced, we believe the balance as of September 30, 2023 will be fully recovered. We did not make any additional payments in 2023 to the vendor assisting us with installations related to projects provided to us through our China Business Partner, and we were able to complete installations that reduced the deferred cost of revenue balance associated with that vendor which caused the net decrease in deferred cost of revenue.

We completed certain projects in China during the three months ended September 30, 2023 worth approximately $1.4 million, but for which the agreement between us and the customer has not yet met the criteria for revenue recognition. If such agreement had qualified for revenue recognition, $1.2 million of cost of sales would have been recognized, further reducing the balance of deferred cost of revenue.


Table of Contents			16			Financial Statement Index

NOTE 7. PREPAID EXPENSE AND OTHER CURRENT ASSETS

The following table presents the components of prepaid expense and other current assets (in thousands):




	September 30, 2023		December 31, 2022


Other receivables	2		23
Prepaid expense	547		1,144
Deposits	245		201

Other current assets	7		6
Total	$	801	$	1,374

During the nine months ended September 30, 2023, we recorded an impairment of approximately $0.2 million related to certain prepaid expense amounts which were deemed unrecoverable.

NOTE 8. PROPERTY AND EQUIPMENT

Property and equipment consist of the following (in thousands, except estimated lives):




	Estimated Life (Years)	September 30, 2023		December 31, 2022
Vehicles	3	$	153	153
Computers and equipment	3	1,193		$	1,170
Furniture and fixtures	3	42		42
Software	3	5,819		5,160
Leasehold improvements	3	206		204
Software development in progress		—		1,199
Total property, equipment and software		$	7,413	$	7,928
Less accumulated depreciation		(6,307)		(6,229)
Total property, equipment and software, net		$	1,106	$	1,699

For the nine months ended September 30, 2023 and 2022, depreciation (and amortization of software) expense was approximately $0.2 million, while during the nine months ended September 30, 2022 depreciation (and amortization of software) expense was de minimis.

During the nine months ended September 30, 2023, we determined that certain costs that we had capitalized to software development in progress would no longer be recoverable and we recorded an impairment of approximately $0.2 million.


Table of Contents			17			Financial Statement Index

NOTE 9. ACCRUED EXPENSE AND OTHER CURRENT LIABILITIES

The following table presents the components of Accrued expense and other current liabilities (in thousands):




	September 30, 2023		December 31, 2022
Accrued compensation and benefit-related expense	$	2,822	$	1,448
Accrued interest	633		769
Other accrued expense	3,302		2,393
Other payables	2,018		2,234
Operating lease liability - current	367		138
China Cash Bonuses (see Note 15)	14		32
Other current liabilities	197		208
Total	$	9,353	$	7,222

NOTE 10. NOTES PAYABLE (PAST DUE)

The following table presents our notes payable (in thousands) as of:




	September 30, 2023		December 31, 2022
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)	$	16,307	$	14,418
Other notes payable	165		189
Notes payable, net of unamortized discount and debt issuance cost	$	16,472	$	14,607

On December 3, 2021, we entered into senior secured loan agreements (the “Original Mudrick Loan Agreements”) with certain of our subsidiaries as guarantors (the “Guarantors”) and certain institutional lenders affiliated with Mudrick Capital Management, LP (collectively, “Mudrick”), pursuant to which Mudrick extended credit to us consisting of term loans in the aggregate principal amount of $30.0 million (the “Original Mudrick Loans”). The Original Mudrick Loans bore interest at 16.5% per annum until the original maturity date of July 31, 2022 and, following an amendment we entered into with Mudrick in August 2022, bore interest at 18.5% per annum. The amendment also extended the maturity date of the Original Mudrick Loans from July 31, 2022 to October 31, 2022. However, we did not make the required repayment of the Original Mudrick Loans by October 31, 2022, which constituted an event of default under the Original Mudrick Loans and triggered an increase in the interest rate under the Original Mudrick Loans to 20.5%.

In connection with our entry into the Original Mudrick Loan Agreements, we paid Mudrick an upfront fee equal to 5.0% of the amount of the Original Mudrick Loans, which amount was netted against the drawdown of the Original Mudrick Loans. We recorded the upfront fee as a debt discount of $1.5 million, and recorded debt issuance cost totaling $1.1 million. We amortized the discount on the Original Mudrick Loans and the debt issuance cost over the life of the Original Mudrick Loans and, during the year ended December 31, 2022, we amortized $2.2 million of such discount and debt issuance cost.

During the year ended December 31, 2022, we repaid $6.2 million of the principal amount of the Original Mudrick Loans in cash and delivered all of our shares in Sharecare, Inc. to Mudrick on July 11, 2022, in partial settlement of the Original Mudrick Loans, resulting in a further repayment of approximately $9.7 million of the principal amount of the Original Mudrick Loans. As of December 31, 2022, the outstanding balance of the Original Mudrick Loans was $14.4 million, and approximately $0.8 million of accrued interest was included in Accrued expense and other current liabilities. During the three months ended March 31, 2023, prior to the New Mudrick Loan Agreement (defined below) canceling the Original Mudrick Loans, we accrued approximately $0.6 million additional interest expense on the Original Mudrick Loans, of which $0.3 million was paid during such period.


Table of Contents			18			Financial Statement Index

On March 14, 2023, we entered into a Note Purchase Agreement (the “New Mudrick Loan Agreement”) with Mudrick, pursuant to which all of the Original Mudrick Loans were cancelled in exchange for new notes payable to Mudrick (the “New Mudrick Notes”) in the aggregate principal amount of approximately $16.3 million. The principal balance of the New Mudrick Notes included the $14.4 million outstanding balance of the Original Mudrick Loans, plus $1.1 million of accrued interest on the Original Mudrick Loans, plus a fee of approximately $0.8 million payable to Mudrick as consideration for cancelling the Original Mudrick Loans and converting all amounts outstanding thereunder into the New Mudrick Notes. We recorded the $0.8 million as interest expense during the three months ended March 31, 2023.

The New Mudrick Notes bear interest at a rate of 20.5% per annum, which is payable on the last business day of each month commencing on May 31, 2023. The interest rate will increase by 2% and the principal amount outstanding under the New Mudrick Notes and any unpaid interest thereon may become immediately due and payable upon the occurrence of any event of default under the New Mudrick Loan Agreement. All amounts outstanding under the New Mudrick Notes, including all accrued and unpaid interest, became due and payable in full on October 31, 2023.

To secure the payment and performance of the obligations under the Original Mudrick Loan Agreements and the New Mudrick Loan Agreement, we, together with certain of our subsidiaries (the “Guarantors”), have granted to TMI Trust Company, as the collateral agent for the benefit of Mudrick, a first priority lien on, and security interest in, all assets of Remark and the Guarantors, subject to certain customary exceptions.

We did not make required repayments of the outstanding loans under the New Mudrick Loan Agreement that were due beginning on June 30, 2023, which constitute events of default for which we have not received a waiver as of the date of this Form 10-Q. While we are actively engaged in discussions with Mudrick regarding a resolution of the events of default and have made progress in such discussions, we cannot provide any assurance that we will be successful in obtaining a waiver or that Mudrick will continue to forebear from taking any enforcement actions against us.

Other Notes Payable

The Other notes payable in the table above represent individually immaterial notes payable issued for the purchase of operating assets. Such notes payable bear interest at a weighted-average interest rate of approximately 6.2% and have a weighted-average remaining term of approximately 4.5 years.


Table of Contents			19			Financial Statement Index

NOTE 11. OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC)

Convertible Debentures

On October 6, 2022, we entered into a debenture purchase agreement (the “2022 Debenture Purchase Agreement”) and a purchase agreement (the “ELOC Purchase Agreement”) with Ionic. Pursuant to the 2022 Debenture Purchase Agreement, we issued a convertible subordinated debenture in the original principal amount of approximately $2.8 million (the “2022 Debenture”) to Ionic for a purchase price of $2.5 million. The 2022 Debenture automatically converted into shares of our common stock (the “2022 Debenture Settlement Shares”) on November 17, 2022 upon the effectiveness of a registration statement we filed pursuant to a registration rights agreement we entered into with Ionic. Upon issuance of the 2022 Debenture, we initially estimated the obligation to issue common stock at approximately $3.6 million. As of December 31, 2022, we estimated such obligation to have a fair value of $1.9 million, representing an additional 1,720,349 shares to be issued pursuant to the 2022 Debenture. When the measurement period for determining the conversion price of the 2022 Debenture was completed, we determined that the final number of 2022 Debenture Settlement Shares would be 3,129,668 (inclusive of 898,854 shares that were issued during 2022), resulting in the issuance of an additional 2,230,814 shares during 2023 with a fair value of $3.1 million.

On March 14, 2023, we entered into a new debenture purchase agreement (the “2023 Debenture Purchase Agreement”) with Ionic pursuant to which we authorized the issuance and sale of two convertible subordinated debentures in the aggregate principal amount of approximately $2.8 million for an aggregate purchase price of $2.5 million. The first debenture is in the original principal amount of approximately $1.7 million for a purchase price of $1.5 million (the “First 2023 Debenture”), which was issued on March 14, 2023, and the second debenture is in the original principal amount of approximately $1.1 million for a purchase price of $1.0 million (the “Second 2023 Debenture” and collectively with the First Debenture, the “2023 Debentures”), which was issued on April 12, 2023. Upon issuance of the First 2023 Debenture and the Second 2023 Debenture, we initially estimated the obligations to issue common stock at an aggregate of approximately $4.1 million, or equivalent estimated issuable shares of 3,669,228. As of September 30, 2023, we estimated that an aggregate total of 9,373,457 shares would be issued upon conversion in full of the 2023 Debentures, representing obligations with an aggregate fair value of $4.7 million.

The 2023 Debentures accrue interest at a rate of 10% per annum, of which two years of interest is guaranteed and deemed earned in full on the first day following the issuance date. The interest rate on the 2023 Debentures increases to a rate of 15% per annum if the 2023 Debentures are not fully paid, converted or redeemed by the second anniversary of each debenture (each, a “Maturity Date”) or upon the occurrence of certain trigger events, including, but not limited to, the suspension from trading or the delisting of our common stock from Nasdaq for three consecutive trading days. If the 2023 Debentures are not fully paid or converted by their respective Maturity Dates, the original aggregate principal amount of the 2023 Debentures will be deemed to have been approximately $3.3 million from their issuance dates.

The 2023 Debentures automatically convert into shares of common stock at the earlier of (i) the effectiveness of the initial registration statement registering the resale of certain Registrable Securities as such term is defined in the Registration Rights Agreement (as defined below) including, without limitation, the shares issuable upon conversion of the 2023 Debentures (the “Conversion Shares”) (such registration statement, the “Resale Registration Statement”), and (ii) 181 days after the issuance date of each 2023 Debenture. The number of shares of common stock issuable upon conversion of each 2023 Debenture shall be determined by dividing the outstanding balance under each 2023 Debenture (including all accrued and unpaid interest and accrued and unpaid late charges, if any) by a conversion price that is the lower of (x) 80% (or 70% if our common stock is not then trading on Nasdaq) of the average of the two lowest VWAPs over a specified measurement period following the conversion date (the “Variable Conversion Price”), and (y) $1.40 (the “Fixed Conversion Price”), subject to full ratchet anti-dilution protection in the event we issue certain equity securities at a price below the then Fixed Conversion Price. The 2023 Debentures are unsecured and expressly junior to any of our existing or future debt obligations. Notwithstanding anything to the contrary, under no circumstances shall the Variable Conversion Price be less than the floor price of $0.20 as specified in the 2023 Debentures. Additionally, in the event of a bankruptcy, we are required to redeem the 2023 Debentures in cash in an amount equal to the then outstanding balance of the 2023 Debentures multiplied by 120%. The 2023 Debentures further provide that we will not effect the conversion of any portion of the 2023 Debentures, and the holder thereof will not have the right to a conversion of any portion of the 2023 Debentures, to the extent that after giving effect to such conversion, the holder together with its affiliates would beneficially own more than 4.99% of the outstanding shares of our common stock immediately after giving effect to such conversion. Furthermore, we may not issue shares of common stock underlying the 2023 Debentures if such issuance would require us to obtain stockholder approval under the Nasdaq rules or until such stockholder approval has been obtained.

Concurrently with entering into the 2023 Debenture Purchase Agreement, we also entered into a registration rights agreement with Ionic (the “2023 Registration Rights Agreement”), pursuant to which we agreed to file with the SEC one or more registration statements, as necessary, and to the extent permissible and subject to certain exceptions, to register under the


Table of Contents			20			Financial Statement Index

Securities Act of 1933, as amended, the resale of the shares of our common stock issuable upon conversion of the 2023 Debentures and the shares of common stock that may be issued to Ionic if we fail to comply with our obligations in the 2023 Registration Rights Agreement. The 2023 Registration Rights Agreement required that we file, within 15 calendar days after we filed our 2022 Form 10-K, a resale registration statement and use commercially reasonable efforts to have such resale registration statement declared effective by the SEC on or before the earlier of (i) 90 days after signing of the 2023 Registration Rights Agreement (or 120 days if such registration statement was subject to full review by the SEC) and (ii) the 2nd business day after we were notified we would not be subject to further SEC review. If we failed to file or have the resale registration statement declared effective by the specified deadlines, then in each instance, we would be required to issue to Ionic 150,000 shares of our common stock within two trading days after such failure, and with respect to the Conversion Shares, we would additionally pay in cash, as liquidated damages, an amount equal to 2% of the amount then currently outstanding under the 2023 Debentures for failure to file and have the Resale Registration Statement declared effective by the same deadlines set forth above for each 30-day period after each such failure. The Resale Registration Statement was filed on June 16, 2023 and declared effective on June 26, 2023. Because we did not meet the filing and effectiveness deadlines specified in the Registration Rights Agreement, we issued 300,000 shares of our common stock shares to Ionic in July 2023, fulfilling the liability of approximately $0.3 million that was outstanding as of June 30, 2023.

Equity Line of Credit

The ELOC Purchase Agreement, as amended (see below), provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right to direct Ionic to purchase up to an aggregate of $50.0 million of shares of our common stock over the 36-month term of the ELOC Purchase Agreement. Under the ELOC Purchase Agreement, after the satisfaction of certain commencement conditions, including, without limitation, the effectiveness of a resale registration statement filed with the SEC registering such shares and that the 2022 Debenture shall have been fully converted into shares of common stock or shall otherwise have been fully redeemed and settled in all respects in accordance with the terms of the 2022 Debenture, we have the right to present Ionic with a purchase notice (each, a “Purchase Notice”) directing Ionic to purchase any amount up to $3.0 million of our common stock per trading day, at a per share price equal to 90% (or 80% if our common stock is not then trading on Nasdaq) of the average of the two lowest volume-weighted average prices (“VWAPs”) over a specified measurement period. With each purchase under the ELOC Purchase Agreement, we are required to deliver to Ionic an additional number of shares equal to 2.5% of the number of shares of common stock deliverable upon such purchase. The number of shares that we can issue to Ionic from time to time under the ELOC Purchase Agreement shall be subject to the condition that we will not sell shares to Ionic to the extent that Ionic, together with its affiliates, would beneficially own more than 4.99% of the outstanding shares of our common stock immediately after giving effect to such sale (the “Beneficial Ownership Limitation”).

In addition, Ionic will not be required to buy any shares of our common stock pursuant to a Purchase Notice on any trading day on which the closing trade price of our common stock is below $0.20 (as amended by the Letter Agreement, as defined below). We will control the timing and amount of sales of our common stock to Ionic. Ionic has no right to require any sales by us, and is obligated to make purchases from us as directed solely by us in accordance with the ELOC Purchase Agreement. The ELOC Purchase Agreement provides that we will not be required or permitted to issue, and Ionic will not be required to purchase, any shares under the ELOC Purchase Agreement if such issuance would violate Nasdaq rules, and we may, in our sole discretion, determine whether to obtain stockholder approval to issue shares in excess of 19.99% of our outstanding shares of common stock if such issuance would require stockholder approval under Nasdaq rules. Ionic has agreed that neither it nor any of its agents, representatives and affiliates will engage in any direct or indirect short-selling or hedging our common stock during any time prior to the termination of the ELOC Purchase Agreement.

The ELOC Purchase Agreement may be terminated by us at any time after commencement, at our discretion; provided, however, that if we sold less than $25.0 million to Ionic (other than as a result of our inability to sell shares to Ionic as a result of the Beneficial Ownership Limitation, our failure to have sufficient shares authorized or our failure to obtain stockholder approval to issue more than 19.99% of our outstanding shares), we will pay to Ionic a termination fee of $0.5 million, which is payable, at our option, in cash or in shares of common stock at a price equal to the closing price on the day immediately preceding the date of receipt of the termination notice. Further, the ELOC Purchase Agreement will automatically terminate on the date that we sell, and Ionic purchases, the full $50.0 million amount under the agreement or, if the full amount has not been purchased, on the expiration of the 36-month term of the ELOC Purchase Agreement.

On January 5, 2023, we and Ionic entered into a letter agreement (the “Letter Agreement”) which amended the ELOC Purchase Agreement. Under the Letter Agreement, the parties agreed, among other things, to (i) amend the floor price below which Ionic will not be required to buy any shares of our common stock under the ELOC Purchase Agreement from $0.25 to $0.20, determined on a post-reverse split basis, (ii) amend the per share purchase price for purchases under the ELOC Purchase Agreement to 90% of the average of the two lowest daily VWAPs over a specified measurement period, which will commence


Table of Contents			21			Financial Statement Index

at the conclusion of the applicable measurement period related to the 2022 Debenture and (iii) waive certain requirements in the ELOC Purchase Agreement to allow for a one-time $0.5 million purchase under the ELOC Purchase Agreement.

As partial consideration for the waiver to allow for the $0.5 million purchase by Ionic, we agreed to issue to Ionic that number of shares (the “Letter Agreement Shares”) equal to the difference between (x) the variable conversion price in the 2022 Debenture, and (y) the calculation achieved as a result of the following formula: 80% (or 70% if our common stock is not then trading on Nasdaq) of the lowest VWAP starting on the trading day immediately following the receipt of pre-settlement conversion shares following the date on which the 2022 Debenture automatically converts or other relevant date of determination and ending the later of (a) 10 consecutive trading days after (and not including) the Automatic Conversion Date (as defined in the ELOC Agreement) or such other relevant date of determination and (b) the trading day immediately after shares of our common stock in the aggregate amount of at least $13.9 million shall have traded on Nasdaq. As of March 31, 2023, we estimated the obligation to issue the Letter Agreement Shares at approximately $0.2 million. As of June 30, 2023, we had issued all of the 200,715 Letter Agreement Shares.

During the nine months ended September 30, 2023, Ionic advanced to us an aggregate of $7.0 million (the "ELOC Advances") pursuant to the ELOC Agreement, as amended. Upon issuance of the ELOC Advances, we initially estimated the obligations to issue common stock at approximately $10.5 million, or equivalent estimated issuable shares of 11,326,803. In partial settlement of our obligation to issue common stock under the ELOC Advances, we issued 5,343,762 shares of our common stock during the period ended September 30, 2023 at aggregate fair value of approximately $5.2 million. As of September 30, 2023, we estimated that an additional 9,046,830 shares would be issued in settlement of our obligation to issue common stock under the ELOC Advances, representing an obligation with an aggregate fair value of $4.5 million.

On September 15, 2023, we and Ionic entered into a letter agreement (the “September 2023 Letter Agreement”) which amends the ELOC Purchase Agreement, as previously amended on January 5, 2023. Under the September 2023 Letter Agreement, the parties agreed, among other things, to (i) allow Remark to deliver one or more irrevocable written notices (“Exemption Purchase Notices”) to Ionic in a total aggregate amount not to exceed $20.0 million, which total aggregate amount shall be reduced by the aggregate amount of previous Exemption Purchase Notices, (ii) amend the per share purchase price for purchases under an Exemption Purchase Notice to 80% of the average of the two lowest daily volume-weighted average prices (“VWAPs”) over a specified measurement period, (iii) amend the definition of the specified measurement period to stipulate that, for purposes of calculating the final purchase price, such measurement period begins the trading day after Ionic pays Remark the amount requested in the purchase notice, while the calculation of the dollar volume of Remark common stock traded on the principal market to determine the length of the measurement period shall begin on the trading day after the previous measurement period ends, iv) that any additional Exemption Purchase Notices that are not in accordance with the terms and provisions of the Purchase Agreement shall be subject to Ionic’s approval, v) to amend section 11(c) of the ELOC Purchase Agreement to increase the Additional Commitment Fee from $0.5 million to $3.0 million and vi) that by September 29, 2023, the parties will amend the Debenture Transaction Documents to include a so-called Most Favored Nation provision that will provide Ionic with necessary protection against any future financing, settlement, exchange or other transaction whether with an existing or new lender, investor or counterparty, and that, if such amendment is not made by September 29, 2023, the Additional Commitment Fee shall be further increased to approximately $3.8 million.

Accounting for the Debentures and the ELOC

Using the guidance in ASC Topic 480, Distinguishing Liabilities from Equity, we evaluated the 2022 Debenture Purchase Agreement and its associated 2022 Debenture, the 2023 Debenture Purchase Agreement and its associated First 2023 Debenture, and the ELOC Purchase Agreement and its associated Letter Agreement and ELOC Advance, and determined that all represented obligations that must or may be settled with a variable number of shares, the monetary value of which was based solely or predominantly on a fixed monetary amount known at inception. Using a Level 3 input, we estimated the number of shares of our common stock that we would have to issue for each obligation and multiplied the estimated number of shares by the closing market price of our common stock on the measurement date to determine the fair value of the obligation. We then recorded the amount of the initial obligation in excess of the purchase price as finance cost. We remeasure each obligation at every balance sheet date until all shares representing the obligation have been issued, with the change in the amount of the obligation being recorded as finance cost. The following table shows the changes in our obligations to issue common stock (dollars in thousands):


Table of Contents			22			Financial Statement Index


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Obligations to Issue Common Stock
Balance at December 31, 2022	$	1,892	$	—	$	—	$	—	$	—	$	1,892
Establishment of new obligation to issue shares	—		4,109		332		249		10,483		15,173
Issuance of Shares	(3,138)		(94)		(294)		(227)		(5,167)		(8,920)
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Balance at September 30, 2023	$	—	$	4,673	$	—	$	—	$	4,511	$	9,184

Estimated Number of Shares Issuable
Balance at December 31, 2022	1,720,349		—		—		—		—		1,720,349
Establishment of new obligation to issue shares	—		3,669,228		300,000		200,715		11,326,803		15,496,746
Issuance of Shares	(2,230,814)		(97,000)		(300,000)		(200,715)		(5,343,762)		(8,172,291)
Change in estimated number of shares issuable	510,465		5,801,229		—		—		3,063,789		9,375,483
Balance at September 30, 2023	—		9,373,457		—		—		9,046,830		18,420,287

The following table shows the composition of finance cost associated with our obligations to issue common stock (dollars in thousands):


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Initial obligation in excess of purchase price	$	—	$	1,609	$	332	$	249	$	3,483	$	5,673
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Total	$	1,246	$	2,267	$	294	$	227	$	2,678	$	6,712

NOTE 12. COMMITMENTS AND CONTINGENCIES

At September 30, 2023, we had no material commitments outside the normal course of business.

Contingencies

As of September 30, 2023, we were neither a defendant in any material pending legal proceeding nor are we aware of any material threatened claims against us and, therefore, we have not accrued any contingent liabilities.

Registration Rights Agreement

On September 27, 2021, we entered into a securities purchase agreement (the “Armistice Purchase Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice Capital”) pursuant to which we issued shares of our common stock together with warrants to purchase our common stock, subject to certain customary anti-dilution adjustments (the “Armistice Warrants”).

In connection with our entry into the Armistice Purchase Agreement, we also entered into a registration rights agreement with Armistice Capital, pursuant to which we were obligated to file one or more registration statements, as necessary, to register under the Securities Act of 1933, as amended, the resale of the shares we issued to Armistice Capital and the shares underlying the Armistice Warrants (collectively, the “Armistice Registrable Securities”) and to obtain effectiveness of such registration statement no later than 90 days following September 27, 2021. The registration rights agreement provided that if we failed to


Table of Contents			23			Financial Statement Index

satisfy our obligation to timely obtain effectiveness, we would incur a penalty of as much as $1.0 million. The registration statement to register the resale of the Armistice Registrable Securities was declared effective on October 31, 2022. We had accrued the maximum penalty and, as of December 31, 2022, paid $0.2 million of such amount, resulting in an unpaid amount of $0.8 million included in other accrued expense as of September 30, 2023.

NOTE 13. STOCKHOLDERS' DEFICIT

Warrants

The following table summarizes information related to our equity-classified stock warrant issuances as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	1,011,441	$	40.10	3.7	$	—
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	—	—
Outstanding at September 30, 2023	1,011,441	$	40.10	2.9	$	—

Share-Based Compensation

We are authorized to issue equity-based awards under our 2014 Incentive Plan, our 2017 Incentive Plan and our 2022 Incentive Plan, each of which our stockholders have approved. We also award cash bonuses (“China Cash Bonuses”) to our employees in China, which grants are not subject to a formal incentive plan and which can only be settled in cash. We grant such awards to attract, retain and motivate eligible officers, directors, employees and consultants. Under each of the plans, we have granted shares of restricted stock and options to purchase common stock to our officers and employees with exercise prices equal to or greater than the fair value of the underlying shares on the grant date.

Stock options and China Cash Bonuses generally expire 10 years from the grant date. All forms of equity awards and China Cash Bonuses vest upon the passage of time, the attainment of performance criteria, or both. When participants exercise stock options, we issue any shares of our common stock resulting from such exercise from new authorized and unallocated shares available at the time of exercise.


Table of Contents			24			Financial Statement Index

The following table summarizes activity under our equity incentive plans related to equity-classified stock option grants as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	1,626,631	$	30.31	5.5	$	1
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	(3,285)	46.75
Outstanding at September 30, 2023	1,623,346	$	30.28	5.0	$	—

Exercisable at December 31, 2022	1,549,681	31.41		5.3	$	1
Exercisable at September 30, 2023	1,601,649	30.79		4.6	$	—

The following table summarizes activity related to our liability-classified China Cash Bonuses as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	71,450	$	35.99	6.1	$	—
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	—	—
Outstanding at September 30, 2023	71,450	$	35.99	5.4	$	—

Exercisable at December 31, 2022	68,450	36.97		6.1	$	—
Exercisable at September 30, 2023	71,450	35.99		5.4	$	—

The following table presents the change in the liability associated with our China Cash Bonuses included in Accrued expense and other current liabilities (in thousands):


	Nine Months Ended September 30,		Year Ended December 31,
	2023		2022
Balance at beginning of period	$	32	$	439
Share-based compensation expense related to China Cash Bonuses	(18)		(407)
Balance at end of period	$	14	$	32


Table of Contents			25			Financial Statement Index

The following table presents a breakdown of share-based compensation cost included in operating expense (in thousands):


	Nine Months Ended September 30,
	2023		2022
Stock options	$	167	$	1,525
China Cash Bonuses	(18)		(340)
Total	$	149	$	1,185

We record share-based compensation expense in the books of the subsidiary that incurs the expense, while for equity-classified stock options we record the change in additional paid-in capital on the corporate entity because the corporate entity’s equity underlies such stock options.

The following table presents information regarding unrecognized share-based compensation cost associated with stock options and China Cash Bonuses:


			September 30, 2023
Unrecognized share-based compensation cost for non-vested awards (in thousands):
Stock options			31
China Cash Bonuses			—
Weighted-average years over which unrecognized share-based compensation expense will be recognized:
Stock options			1.4
China Cash Bonuses			0

NOTE 14. RELATED PARTY TRANSACTIONS

As of September 30, 2023, we owed approximately $1.0 million to members of management representing various operating expense payments made on our behalf.

NOTE 15. CHINA BUSINESS PARTNER

We interact with an unrelated entity (the “China Business Partner”) in more than one capacity. Firstly, since 2020, we have been working with the China Business Partner to earn revenue by obtaining business from some of the largest companies in China. Secondly, our artificial intelligence business in the U.S. has purchased substantially all of its inventory from a subsidiary of the China Business Partner which manufactures certain equipment to our specifications; though, during the nine months ended September 30, 2023, we did not make any such purchases. In addition, a member of our senior leadership team maintains a role in the senior management structure of the China Business Partner.

During the nine months ended September 30, 2023 and 2022, we recognized approximately $0.1 million and $5.3 million, respectively, of revenue from the relationship with the China Business Partner. At September 30, 2023 and December 31, 2022, in addition to the outstanding accounts receivable balances from the China Business Partner described in Note 5, we had outstanding accounts payable to the China Business Partner of $0.7 million and $0.7 million, respectively.

NOTE 16. SUBSEQUENT EVENTS

Ionic Transactions

In November 2023, Ionic advanced to us approximately $0.6 million pursuant to the ELOC Agreement, as amended.

During October 2023 and November 2023, we issued a total of 1,220,000 shares to Ionic in partial settlement of ELOC Advances.


Table of Contents			26			Financial Statement Index

On November 18, 2023, we and Ionic entered into a letter agreement (the “November 2023 Letter Agreement”) which, among other things, amends the Subordinated Convertible Debenture, dated as of March 14, 2023, by and between Remark and Ionic (the “First 2023 Debenture”).

The November 2023 Letter Agreement amends the First 2023 Debenture to include language that requires us to notify Ionic if we enter into any new debt agreement after November 18, 2023 or modify any debt agreement that existed at November 18, 2023. If Ionic determines that the terms of such new or modified agreements are preferable to the terms of the First 2023 Debenture, Ionic can give us written notice to amend, within five days, the terms of the First 2023 Debenture, excluding principal and interest, to give Ionic the benefit of such preferable terms.

Failure to Maintain Continued Listing Standards

In accordance with Nasdaq Listing Rule 5810(c)(2)(A), on June 12, 2023 we submitted a plan to regain compliance with the Continued Listing Standards to the Nasdaq Listing Qualifications Department. On July 24, 2023, the Nasdaq Listing Qualifications Department notified us that it was granting us until October 24, 2023 (the “Extension Period”) to file a report with the SEC and Nasdaq stating that we have successfully executed our plan to regain compliance with the Continued Listing Standards and that we did in fact regain such compliance. We were not able to regain compliance with the Continued Listing Standards by October 24, 2023 and, on October 26, 2023, we received a staff determination letter from Nasdaq indicating that we did not regain compliance with the Continued Listing Standards and that, unless we request an appeal of Nasdaq’s determination, our common stock was subject to delisting.

We appealed Nasdaq’s delisting determination to a Hearings Panel (the “Panel”) and were notified by Nasdaq that we have been granted a hearing with the Panel on February 1, 2024. Our common stock will continue to be listed and traded on the Nasdaq Capital Market pending a decision by the Panel.


Table of Contents			27			Financial Statement Index

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read our discussion and analysis of our financial condition and results of operations for the three months ended September 30, 2023 in conjunction with our condensed consolidated financial statements and notes thereto set forth in Part I, Item 1 of this Form 10-Q. Such discussion and analysis includes forward-looking statements that involve risks and uncertainties and that are not historical facts, including statements about our beliefs and expectations. You should also read Business, Risk Factors and Special Note Regarding Forward-Looking Statements in this Form 10-Q.

OVERVIEW

We are a diversified global technology business with leading AI and data-analytics, as well as a portfolio of digital media properties.

OUR BUSINESS

Corporate Structure

We are a holding company incorporated in Delaware and not a Chinese operating company. As a holding company, we conduct most of our operations through our subsidiaries, each of which is wholly owned. Until September 2022, we had historically conducted a significant part of our operations through contractual arrangements between our WFOE and certain VIEs based in China to address challenges resulting from laws, policies and practices that may disfavor foreign-owned entities that operate within industries deemed sensitive by the Chinese government. We were the primary beneficiary of the VIEs because the contractual arrangements governing the relationship between the VIEs and our WFOE, which included an exclusive call option agreement, exclusive business cooperation agreement, a proxy agreement and an equity pledge agreement, enabled us to (i) exercise effective control over the VIEs, (ii) receive substantially all of the economic benefits of the VIEs, and (iii) have an exclusive call option to purchase, at any time, all or part of the equity interests in and/or assets of the VIEs to the extent permitted by Chinese laws. Because we were the primary beneficiary of the VIEs, we consolidated the financial results of the VIEs in our consolidated financial statements in accordance with GAAP.


Table of Contents			28			Financial Statement Index


Table of Contents			29			Financial Statement Index

significantly decline or become worthless. In recent years, the Chinese government adopted a series of regulatory actions and issued statements to regulate business operations in China, including those related to the use of variable interest entities, cybersecurity, data security, export control and anti-monopoly concerns. As of the date of this Form 10-Q, we have neither been involved in any investigations on cybersecurity review initiated by any Chinese regulatory authority, nor received any inquiry, notice or sanction. As of the date of this Form 10-Q, no relevant laws or regulations in China explicitly require us to seek approval from the CSRC for any securities listing. As of the date of this Form 10-Q, we have not received any inquiry, notice, warning or sanctions regarding our planned overseas listing from the CSRC or any other Chinese governmental authorities relating to securities listings. However, since these statements and regulatory actions are newly published, official guidance and related implementation rules have not all been issued. It is highly uncertain what potential impact such modified or new laws and regulations will have on our ability to conduct our business, accept investments or list or maintain a listing on a U.S. or foreign exchange.

As of the date of this Form 10-Q, we are not required to seek permissions from the CSRC, the CAC or any other entity that is required to approve our operations in China. Nevertheless, Chinese regulatory authorities may in the future promulgate laws, regulations or implement rules that require us or our subsidiaries to obtain permissions from such regulatory authorities to approve our operations or any securities listing.

Holding Foreign Companies Accountable Act

The HFCA Act was enacted on December 18, 2020. The HFCA Act states that if the SEC determines that a company has filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for three consecutive years beginning in 2021, the SEC shall prohibit such shares from being traded on a national securities exchange or in the over the counter trading market in the United States. On December 2, 2021, the SEC adopted amendments to finalize rules implementing the submission and disclosure requirements in the HFCA Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB is unable to inspect or investigate completely because of a position taken by an authority in a foreign jurisdiction. The Consolidated Appropriations Act, 2023, which was signed into law on December 29, 2022, amended the HFCA Act to reduce the number of consecutive non-inspection years required to trigger the trading prohibition under the HFCA Act from three years to two years.

On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed the Protocol, taking the first step toward opening access for the PCAOB to completely inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong.


Table of Contents			30			Financial Statement Index

Transfer of Cash or Assets

Dividend Distributions

As of the date of this Form 10-Q, none of our subsidiaries have made any dividends or distributions to Remark.

The Chinese government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of China. Therefore, we may experience difficulties in completing the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from our profits, if any. If we are unable to receive all of the revenues from our operations through our China-based subsidiaries, we may be unable to pay dividends on our common stock.

AI Business

We generate revenue by using the proprietary data and AI software platform we developed to deliver AI-based computer vision products, computing devices and software-as-a-service solutions for businesses in many industries. We continue to partner with top universities on research projects targeting algorithm, artificial neural network and computing architectures which we believe will keep us among the leaders in technology development.

The primary focus of our business is promoting and facilitating the safety of our customers and their customers through our Smart Safety Platform (the “SSP”). The SSP, having won numerous industry and government benchmark tests for accuracy and speed, is a leading software solution for using computer vision to detect persons, objects and behavior in video feeds. Real-time alerts from the SSP allow operations staff to respond rapidly to prevent any events or activities that can endanger public security or workplace safety.

We deploy the SSP to integrate with each customer’s IT infrastructure, including, in many cases, cameras already in place at the customer’s location(s). When necessary, we also sell and deploy hardware to create or supplement the customer’s monitoring capabilities. Such hardware includes, among other items, cameras, edge computing devices and/or our Smart Sentry units. The Smart Sentry is a large mobile camera unit with a telescoping mast on which a high-quality camera is mounted. Based upon customer needs, the camera may have either standard vision and/or thermal vision capability. The camera works in conjunction with an edge computing device that is also mounted to the unit. The Smart Sentry is an example of how we incorporate the SSP in modern IT architectural concepts, including edge computing and micro-service architectures. Edge computing, for example, allows the SSP to conduct expensive computing tasks at distributed locations without requiring large data transmission over the internet, thereby dramatically reducing costs while integrating numerous and varied sensors at distributed locations.


Table of Contents			31			Financial Statement Index

We customize and sell our innovative AI-based computer vision products and solutions, including the SSP, to customers in the retail, construction, public safety, workplace safety and public sector markets. We have also developed versions of our solutions for application in the transportation and energy markets.

Overall Business Outlook

Two primary factors have been affecting our business in recent quarters and occupying our focus as we plan for the future. While we have been dealing with a slow economic recovery in China as municipalities and businesses there try to return to fully-normalized operations following strict preventative measures related to the COVID-19 pandemic, political tensions between the U.S. and China have continued to increase over recent months to a point that such tensions have also impacted our ability to complete projects in China as quickly as we have in the past and as quickly as we had planned during 2023. Management is optimistic that tensions between the U.S. and China will begin to relax after the most-recent summit between such countries’ leaders, but we expect that we may continue to face difficult-to-predict operating results in China for approximately the next 12 months.

While we will continue to work with customers in China, we have been responding to the pandemic-related challenges and political tensions by looking for opportunities to expand our business in the Asia-Pacific region outside of China, where we believe there still are fast-growth AI market opportunities for our solutions, as well as by spending increasing amounts of effort over the past several quarters developing business opportunities in the United States, the U.K., and in Central and South America, where we see demand for AI products and solutions in the workplace, government and public safety markets. During the nine months ended September 30, 2023, we began sales in the U.K. and Brazil, while during the three months ended September 30, 2023, we successfully signed initial contracts to expand our sales into Colombia, Malaysia, and India. Given the lack in those three respective countries and in Brazil of AI companies specializing in computer vision, we believe we have a first-mover advantage with regard to targeting the same industries that we have successfully targeted in China and which we have targeted in the U.S. and U.K. In addition, we anticipate expanding sales into the Middle East during the first quarter of 2024.

In conjunction with the geographic diversification of our business, we believe we can more rapidly and more efficiently develop and increase our market presence in the various industries that we have identified as being most important by establishing business relationships with channel partners. To that end, we have been discussing such relationship possibilities with large, established players in the information technology and burgeoning AI space which could provide us with access to their respective online marketplaces and other sales channels as well.

Despite our efforts, the COVID-19 pandemic, as well as economic and geopolitical conditions in some international regions, could continue to affect our business and we cannot be sure what the ultimate effects will be. We will continue to pursue geographic diversification, but anticipating when, or if, we can close on the opportunities in front of us is difficult. In addition, we may face a large number of well-known competitors which would make deploying our software solutions in the market segments we have identified difficult.

Inflation and Supply Chain

Other than the impact of inflation on the general economy, we do not believe that inflation has had a material effect on our operations to date. However, there is a risk that our operating costs could be subject to inflationary pressures in the future, which would have the effect of increasing our operating costs and cause additional stress on our working capital resources.

The high level of political tension described above has affected our ability to work with certain vendors in a timely manner. Though we have been able to complete contracts with our customers in China, such political tension has caused delays in the speed at which we can work with certain vendors to deploy our services and complete contracts in China. Also, as we work to increase our sales of computer-vision products and services in the U.S., Europe and South America and thereby geographically diversify our business, we could be subjected to the risk of supply chain disruptions with regard to high-technology products such as servers and related equipment that we use to train our AI software algorithms and which we plan to sell to customers to support operation of our computer-vision products and services.


Table of Contents			32			Financial Statement Index

Business Developments During 2023

China’s response to the COVID-19 pandemic, known as the Zero-COVID policy, included lockdowns and/or other severe restrictions on business and daily life in China, which made it difficult for us to interact with our clients and vendors through at least December 2022. As described above, such preventative measures, in addition to a high level of political tension between the U.S. and China, have had lingering economic and operational effects which have made it difficult for us to complete as many projects in China during the nine months ended September 30, 2023 as compared to the same period of the previous year. Our customers have only slowly been able to restart stalled projects or begin new ones. The majority of our completed work was related to a large telecommunications provider in China and concrete producers. We completed certain projects in China during the three months ended September 30, 2023 worth approximately $1.4 million, but the agreement has not yet met the criteria for revenue recognition. Cost associated with the projects for which the agreement has not yet met the criteria for revenue recognition was approximately $1.2 million.

Also, during the three months ended September 30, 2023, we successfully signed initial contracts to expand our sales into Colombia, Malaysia, and India. We have not yet recognized any revenue from such new contracts, and we recognize that these are just the first steps into new markets.

The following table presents our revenue categories as a percentage of total consolidated revenue during the three and nine months ended September 30, 2023 and 2022.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
AI-based products and services	95	%	95	%	96	%	97	%
Advertising and other	5	%	5	%	4	%	3	%

CRITICAL ACCOUNTING ESTIMATES

During the three months ended September 30, 2023, we made no material changes to our critical accounting estimates as we disclosed them in Part II, Item 7 of our 2022 Form 10-K.

RESULTS OF OPERATIONS

The following tables summarize our operating results for the nine months ended September 30, 2023, and the discussion following the table explains material changes in such operating results compared to the nine months ended September 30, 2022.


Table of Contents			33			Financial Statement Index


(dollars in thousands)	Three Months Ended September 30,				Change
	2023		2022		Dollars		Percentage
Revenue, including amounts from China Business Partner	$	183	$	2,812	$	(2,629)	(93)	%

Cost of revenue	254		2,459		(2,205)		(90)	%
Sales and marketing	340		270		70		26	%
Technology and development	768		41		727		1,773	%
General and administrative	2,843		6,726		(3,883)		(58)	%
Depreciation and amortization	107		43		64		149	%

Total cost and expense	4,312		9,539

Interest expense	(949)		(1,365)		416		(30)	%
Finance cost related to obligations to issue common stock	(2,086)		—		(2,086)

Loss on investment	—		(348)		348		(100)	%
Other gain (loss), net	(8)		(493)		485		(98)	%
Provision for income taxes	—		9		(9)		(100)	%
Net loss	(7,172)		(8,924)		1,752		(20)	%


(dollars in thousands)	Nine Months Ended September 30,				Change
	2023		2022		Dollars		Percentage
Revenue, including amounts from China Business Partner	$	4,176	$	10,037	$	(5,861)	(58)	%

Cost of revenue	3,220		8,576		(5,356)		(62)	%
Sales and marketing	1,093		606		487		80	%
Technology and development	1,504		1,004		500		50	%
General and administrative	8,920		14,598		(5,678)		(39)	%
Depreciation and amortization	178		121		57		47	%
Impairments	392		—		392
Total cost and expense	15,307		24,905

Interest expense	(3,351)		(5,325)		1,974		(37)	%
Finance cost related to obligations to issue common stock	(6,712)		—		(6,712)

Loss on investment	—		(26,356)		26,356		(100)	%
Other gain (loss), net	(14)		(342)		328		(96)	%
Provision for income taxes	—		9		(9)		(100)	%
Net loss	(21,208)		(46,882)		25,674		(55)	%


Table of Contents			34

Revenue and Cost of Revenue. During the three months ended September 30, 2023, our project completions slowed in China as business and economic recovery efforts that began after China lifted most of its onerous COVID-19 related restrictions at the end of 2022, as well as the noted political tensions between the U.S. and China, continued to make it more difficult than expected for us to complete projects on a steadily increasing pace. As a result of completing fewer projects than expected, revenue lagged behind our performance in the same period of the prior year, which period included projects associated with our work with an unrelated entity (our China Business Partner).

During the nine months ended September 30, 2023, we were unable to complete as many projects in China as we did in the same period of the prior year, primarily due to the slow and methodical business and economic recovery efforts that are ongoing after China lifted most of its onerous COVID-19 related restrictions at the end of 2022.

Cost of revenue during the three and nine months ended September 30, 2023 decreased, in conjunction with the decreases in project completions described above.

Sales and marketing. The addition in late 2022 of three new personnel, including two executive positions, on our sales team caused an increase of $0.3 million in payroll and related expense during the nine months ended September 30, 2023.

Technology and Development. During the three months ended September 30, 2022, we reclassified a refundable tax credit we received from the government of the United Kingdom resulting from our research and development activities in its jurisdiction from Other gain to technology and development expense. The current-year tax credit was recorded in a previous quarter during 2023. A modest increase in consulting related to our research and development activities also contributed to the increase in technology and development expense.

During the three months ended September 30, 2023, an increase in consulting related to our research and development activities caused the increase in technology and development expense.

General and administrative. During the three months ended September 30, 2023, we did not have to record any reserve for doubtful accounts, while during the comparable period of the prior year we had to re-evaluate the amounts receivable from customers based on what was then recent information and, as a result, we increased our reserve for doubtful accounts by $2.3 million. We experienced a decrease of approximately $0.8 million in legal and other professional fees primarily because the three months ended September 30, 2022 included expense related to financings and the filing of amendments to registration statements whereas we did not have similar activity during the three months ended September 30, 2023. Also contributing to the overall decrease in general and administrative expense was a decrease of $0.3 million in certain expenses related to business development, including short-term work space rentals. Finally, our share-based compensation expense decreased by $0.5 million due to a large batch of stock options with a grant date of July 8, 2021 becoming fully expensed in January 2023, in comparison to having three months of expense recognition during the three months ended September 30, 2022 and due to the decrease in the number of outstanding China Cash Bonuses.

During the nine months ended September 30, 2023, we did not have to record any reserve for doubtful accounts, while during the comparable period of the prior year we had to re-evaluate the amounts receivable from customers based on what was then recent information and, as a result, we increased our reserve for doubtful accounts by $2.3 million. We experienced a decrease of approximately $0.8 million in legal and other professional fees primarily because the nine months ended September 30, 2022 included expense related to financings and the filing of amendments to registration statements whereas we did not have similar activity during the three months ended September 30, 2023. Also contributing to the overall decrease in general and administrative expense was a decrease of $1.5 million in certain expenses related to business development, including short-term work space rentals. Finally, our share-based compensation expense decreased by $1.3 million due to a large batch of stock options with a grant date of July 8, 2021 becoming fully expensed in January 2023, in comparison to having nine months of expense recognition during the nine months ended September 30, 2022 and due to the decrease in the number of outstanding China Cash Bonuses.

Impairments. During the nine months ended September 30, 2023, we determined that certain costs that we had capitalized to software development in progress would no longer be recoverable and we recorded an impairment of approximately $0.2 million. Also, we recorded an impairment of approximately $0.2 million related to certain prepaid expense amounts which were deemed unrecoverable

Interest expense. We executed the Original Mudrick Loan Agreements in December 2021, pursuant to which we obtained the Original Mudrick Loans in the aggregate principal amount of $30.0 million. During the nine months ended September 30,


Table of Contents			35

2022, we recorded in interest expense approximately $2.2 million of amortization of debt discount and debt issuance cost related to the Original Mudrick Loans, but did not have any such amortization during the nine months ended September 30, 2023 because the debt discount and debt issuance cost were fully amortized during 2022. Interest expense also decreased because significantly less debt principal was outstanding on the Original Mudrick Loans during the three and nine months ended September 30, 2023 than during the same period of the prior year, even though the interest rate had increased from 16.5% to 20.5%. Partially offsetting the decreases in interest expense was the amendment and extension fee of approximately $0.8 million we recorded in relation to our entry on March 14, 2023 into the New Mudrick Loan Agreement described, along with the Original Mudrick Loan Agreements, in Note 10 in the Notes to Unaudited Condensed Consolidated Financial Statements included in this Form 10-Q.

Finance Cost Related to Obligations to Issue Common Stock. The finance cost during the three and nine months ended September 30, 2023 resulted from the establishment and remeasurement of obligations to issue our common stock that we incurred in relation to the debentures we issued to Ionic in 2022 and 2023, as well as the ELOC Advances we received from Ionic, all of which is described in Note 11 in the Notes to Unaudited Condensed Consolidated Financial Statements included in this Form 10-Q. We had no similar transactions during the three and nine months ended September 30, 2022.

Loss on investment. On July 1, 2021, as the result of a business combination involving a U.S.-based venture, Sharecare, Inc. (“Legacy Sharecare”) and Falcon Capital Acquisition Corp., a special purpose acquisition company, the common stock of the surviving entity of such business combination (“New Sharecare”) became listed on the Nasdaq Stock Market LLC and our equity in Legacy Sharecare converted into cash and shares of publicly traded common stock of New Sharecare. As a result of the common stock of New Sharecare being traded on a national securities exchange, we were able to remeasure our investment at fair value. Since July 1, 2021, the value of the New Sharecare stock steadily declined, which caused the losses on investment during the three and nine months ended September 30, 2022. On July 11, 2022, we delivered our remaining 6,250,000 shares of New Sharecare to our lender at their request and, as a result, we did not maintain investments during the nine months ended September 30, 2023.

Other gain (loss), net. During the nine months ended September 30, 2022, we accrued $0.4 million of liquidated damages during the second quarter of 2022 related to the Armistice Resale Registration Statement which became effective after the time frame during which we were required to ensure it became effective. We had no similar activity during the nine months ended September 30, 2023.

LIQUIDITY AND CAPITAL RESOURCES

Overview

During the nine months ended September 30, 2023, and in each fiscal year since our inception, we have incurred net losses which have resulted in a stockholders’ deficit of $32.9 million as of September 30, 2023. Additionally, our operations have historically used more cash than they have provided. Net cash used in operating activities was $9.1 million during the nine months ended September 30, 2023. As of September 30, 2023, our cash balance was $0.3 million. Our history of recurring operating losses, working capital deficiencies and negative cash flows from operating activities give rise to, and management has concluded that there is, substantial doubt regarding our ability to continue as a going concern.

Mudrick Loans

On December 3, 2021, we entered into the Original Mudrick Loan Agreements pursuant to which we incurred the Original Mudrick Loans in the aggregate principal amount of $30.0 million. The Original Mudrick Loans initially bore interest at 16.5% per annum until the original maturity date of July 31, 2022 and, following an amendment we entered into with Mudrick in August 2022, bore interest at 18.5% per annum. The amendment also extended the maturity date of the Original Mudrick Loans from July 31, 2022 to October 31, 2022. However, we did not make the required repayment of the Original Mudrick Loans by October 31, 2022, which constituted an event of default under the Original Mudrick Loans and triggered an increase in the interest rate under the Original Mudrick Loans to 20.5%.

On March 14, 2023, we entered into the New Mudrick Loan Agreement pursuant to which all of the Original Mudrick Loans were cancelled in exchange for the New Mudrick Notes in the aggregate principal amount of approximately $16.3 million. The New Mudrick Notes bear interest at a rate of 20.5% per annum, which shall be payable on the last business day of each month commencing on May 31, 2023. The interest rate will increase by 2% and the principal amount outstanding under the New Mudrick Notes and any unpaid interest thereon may become immediately due and payable upon the occurrence of any


Table of Contents			36

event of default under the New Mudrick Loan Agreement. All amounts outstanding under the New Mudrick Notes, including all accrued and unpaid interest, will be due and payable in full on October 31, 2023. See Note 10 in the Notes to Unaudited Condensed Consolidated Financial Statements included in this Form 10-Q for additional information regarding the New Mudrick Notes.

To secure the payment and performance of the obligations under the Original Mudrick Loan Agreements and the New Mudrick Loan Agreement, we, together with the Guarantors, have granted to TMI Trust Company, as the collateral agent for the benefit of Mudrick, a first priority lien on, and security interest in, all assets of Remark and the Guarantors, subject to certain customary exceptions.

In connection with our entry into the Original Mudrick Loan Agreements, we paid to Mudrick an upfront fee equal to 5.0% of the amount of the Original Mudrick Loans, which amount was netted against the drawdown of the Original Mudrick Loans. We recorded the upfront fee as a debt discount of $1.5 million, and recorded debt issuance cost totaling $1.1 million. We amortized the discount on the Original Mudrick Loans and the debt issuance cost over the life of the Original Mudrick Loans and, during the year ended December 31, 2022, we amortized $2.2 million of such discount and debt issuance cost. In consideration for the amendment we entered into with Mudrick in August 2022, we paid Mudrick an amendment and extension fee in the amount of 2.0% of the then unpaid principal balance of the Original Mudrick Loans, which was approximately $0.3 million, by adding such amount to the principal balance of the Original Mudrick Loans.

As of the date of this Form 10-Q, the principal amount outstanding, together with interest on the unpaid principal balance of the New Mudrick Notes, is approximately $17.4 million.

Ionic Transactions

On October 6, 2022, we entered into the 2022 Debenture Purchase Agreement with Ionic, pursuant to which we issued the 2022 Debenture to Ionic for a purchase price of $2.5 million.

In connection with the 2022 Debenture, on October 6, 2022, we also entered into the ELOC Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right to direct Ionic to purchase up to an aggregate of $50.0 million of shares of our common stock over the 36-month term of the ELOC Purchase Agreement. Under the ELOC Purchase Agreement, after the satisfaction of certain commencement conditions, we have the right to present Ionic with a purchase notice directing Ionic to purchase any amount up to $3.0 million of our common stock per trading day, at the purchase price equal to 90% (or 80% if our common stock is not then trading on Nasdaq) of the average of the five lowest VWAPs of our common stock over a specified measurement period. With each purchase under the ELOC Purchase Agreement, we are required to deliver to Ionic an additional number of shares equal to 2.5% of the number of shares of common stock deliverable upon such purchase.

On November 7, 2022, we entered into an amendment to the 2022 Debenture Purchase Agreement with Ionic, pursuant to which we and Ionic agreed to amend and restate the 2022 Debenture to provide that (i) in no event will the conversion price under the 2022 Debenture be below a floor price of $0.10 (such price, as may be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction, the “Floor Price”), and (ii) in the event the actual conversion price is less than the Floor Price, (A) Ionic will be entitled to that number of settlement conversion shares issuable with an assumed conversion price equal to the Floor Price, and (B) we will be required to make a cash payment to Ionic on or prior to the maturity date of an amount that is calculated by subtracting the number of shares of common stock issuable at an assumed conversion price equal to the Floor Price from the number of shares of common stock issuable at the actual conversion price, multiplied by a price equal to the average of the ten lowest VWAPs during the specified measurement period.

On January 5, 2023, we and Ionic entered the Letter Agreement which amended the ELOC Purchase Agreement. Under the Letter Agreement, the parties agreed, among other things, to (i) amend the floor price below which Ionic will not be required to buy any shares of our common stock under the ELOC Purchase Agreement from $0.25 to $0.20, determined on a post-reverse split basis, (ii) amend the per share purchase price for purchases under the ELOC Purchase Agreement to 90% of the average of the two lowest daily VWAPs over a specified measurement period, which will commence at the conclusion of the applicable measurement period related to the 2022 Debenture and (iii) waive certain requirements in the ELOC Purchase Agreement to allow for a one-time $0.5 million purchase under the ELOC Purchase Agreement.

On March 14, 2023, we entered into the 2023 Debenture Purchase Agreement with Ionic pursuant to which we authorized the issuance and sale of two convertible subordinated debentures in the aggregate principal amount of approximately $2.8 million for an aggregate purchase price of $2.5 million. The first debenture is in the original principal amount of approximately $1.7 million for a purchase price of $1.5 million, which was issued on March 14, 2023, and the second debenture is in the


Table of Contents			37

original principal amount of approximately $1.1 million for a purchase price of $1.0 million, which was issued on April 12, 2023.

On September 15, 2023, we and Ionic entered into a letter agreement (the “September 2023 Letter Agreement”) which amends the Purchase Agreement, dated as of October 6, 2022, by and between Remark and Ionic, and as previously amended on January 5, 2023 (the “ELOC Purchase Agreement”). The September 2023 Letter Agreement superceded two previous letter agreements we entered into with Ionic, one in July 2023 and another in August 2023.

Under the September 2023 Letter Agreement, the parties agreed, among other things, to (i) allow Remark to deliver one or more irrevocable written notices (“Exemption Purchase Notices”) to Ionic in a total aggregate amount not to exceed $20.0 million, which total aggregate amount shall be reduced by the aggregate amount of previous Exemption Purchase Notices, (ii) amend the per share purchase price for purchases under an Exemption Purchase Notice to 80% of the average of the two lowest daily volume-weighted average prices (“VWAPs”) over a specified measurement period, (iii) amend the definition of the specified measurement period to stipulate that, for purposes of calculating the final purchase price, such measurement period begins the trading day after Ionic pays Remark the amount requested in the purchase notice, while the calculation of the dollar volume of Remark common stock traded on the principal market to determine the length of the measurement period shall begin on the trading day after the previous measurement period ends, iv) that any additional Exemption Purchase Notices that are not in accordance with the terms and provisions of the Purchase Agreement shall be subject to Ionic’s approval, v) to amend section 11(c) of the ELOC Purchase Agreement to increase the Additional Commitment Fee from $0.5 million to $3.0 million and vi) that by September 29, 2023, the parties will amend the Debenture Transaction Documents to include a so-called Most Favored Nation provision that will provide Ionic with necessary protection against any future financing, settlement, exchange or other transaction whether with an existing or new lender, investor or counterparty, and that, if such amendment is not made by September 29, 2023, the Additional Commitment Fee shall be further increased to approximately $3.8 million.

See Note 11 in the Notes to Unaudited Condensed Consolidated Financial Statements included in this Form 10-Q for additional detail on the Ionic transactions.

General

Our history of recurring operating losses, working capital deficiencies and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern.

We intend to fund our future operations and meet our financial obligations through revenue growth from our AI offerings, as well as through sales of our thermal-imaging products. We cannot, however, provide assurance that revenue, income and cash flows generated from our businesses will be sufficient to sustain our operations in the twelve months following the filing of this Form 10-Q. As a result, we are actively evaluating strategic alternatives including debt and equity financings.

•develop and grow new product line(s)

•obtain additional capital through equity issuances.


Table of Contents			38

Cash Flows - Operating Activities

During the nine months ended September 30, 2023, we used $4.6 million less cash in operating activities than we did during the same period of the prior year. The decrease in cash used in operating activities is primarily the result of the timing of payments related to elements of working capital.

Cash Flows - Investing Activities

Investing activities during the nine months ended September 30, 2023 were de minimis, while the same period during 2022 provided $6.3 million in proceeds from the sale of a portion of our marketable securities.

Cash Flows - Financing Activities

During the nine months ended September 30, 2023, we received $2.5 million from Ionic in exchange for the issuance of convertible debentures, and Ionic also advanced us an aggregate of $7.0 million under the ELOC Purchase Agreement for which we issued 2,641,173 shares of our common stock and for which we expect to issue another estimated 978,168 shares of our common stock. Also during the nine months ended September 30, 2023, we received $1.0 million of advances from senior management representing various operating expense payments and repaid $1.1 million of advances from senior management. During the same period of 2022, we repaid $6.2 million of the Original Mudrick Loans and received $2.4 million of advances from senior management and repaid $1.5 million of advances from senior management representing various operating expense payments made on our behalf.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

Recently Issued Accounting Pronouncements

Please refer to Note 2 in the Notes to Unaudited Condensed Consolidated Financial Statements included in this report for a discussion regarding recently issued accounting pronouncements which may affect us.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain a set of disclosure controls and procedures designed to provide reasonable assurance that the information we must disclose in reports we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. We designed our disclosure controls with the objective of ensuring we accumulate and communicate this information to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under Exchange Act, as of the end of the period covered by this report. Based upon that evaluation, our management, including our principal executive officer and principal financial officer, concluded that, because of the material weaknesses in our internal control over financial reporting related to: (i)


Table of Contents			39

insufficient documentary evidence that we had reviewed information underlying manual journal entries at a sufficient level of detail, (ii) insufficient documentation of our consideration of appropriate revenue recognition criteria for certain contracts arising from our AI business in China, (iii) an aggregation of deficiencies in our monitoring and activity-level controls related to processes in our AI business in China including accounts payable, accrued liabilities, payroll and fixed assets, and (iv) failure to retain documentary evidence of all inventory purchases and the insufficient evaluation of the impact of discounted sales transactions on the valuation of our inventory, all of which we described in our 2022 Form 10-K, our disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2023.

Changes in Internal Control over Financial Reporting

In our 2022 Form 10-K, we disclosed that management had determined that material weaknesses in our internal control over financial reporting (described above) existed. As of the date of this report, the implementation of the plan developed by management to remediate the underlying causes of the material weaknesses and improve the design and operating effectiveness of internal control over financial reporting and our disclosure controls continues. Such implementation has been slowed by various factors, including the COVID-19 pandemic. As a result, there was no change in our internal control over financial reporting during the three months ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and the risk factors discussed in Part I, Item 1A of our 2022 Form 10-K, together with all the other information in this Form 10-Q, including our unaudited condensed financial statements and notes thereto, which could materially affect our business, financial condition or operating results. The risks described below and in our 2022 Form 10-K are not the only risks we face. Additional risks and uncertainties that we are unaware of may become important factors that affect us. If any of these risks actually occur, our business, financial condition or operating results may suffer, the trading price of our common stock could decline, and you may lose all or part of your investment. The following information updates, and should be read in conjunction with the information disclosed in Part I, Item 1A, “Risk Factors,” contained in our 2022 Form 10-K. Except as disclosed below, there have been no material changes from the risk factors disclosed in our 2022 Form 10-K.

We have a history of operating losses and we may not generate sufficient revenue to support our operations.

During the year ended December 31, 2022, and in each fiscal year since our inception, we have incurred net losses and generated negative cash flow from operations, resulting in an accumulated deficit of $(388.5) million as of December 31, 2022 and an accumulated deficit of $(409.7) million as of September 30, 2023. In addition, for the nine months ended September 30, 2023, we had a net loss of $(21.2) million.

We cannot provide assurance that revenue generated from our businesses will be sufficient to sustain our operations in the long term. As a result, we are actively evaluating strategic alternatives including debt and equity financings. Should we fail to successfully implement our plans described herein, such failure would have a material adverse effect on our business, including the possible cessation of operations.

Conditions in the debt and equity markets, as well as the volatility of investor sentiment regarding macroeconomic and microeconomic conditions (in particular, as a result of the COVID-19 pandemic, global supply chain disruptions, inflation and other cost increases, and the geopolitical conflict in Ukraine) will play primary roles in determining whether we can successfully obtain additional capital. We cannot be certain that we will be successful at raising capital, whether in an equity financing or debt financing, on commercially reasonable terms, if at all. In addition, if we obtain capital by issuing equity, such transaction(s) may dilute existing stockholders.


Table of Contents			40			Financial Statement Index

We may not have sufficient cash to repay our outstanding senior secured indebtedness.

As of September 30, 2023, the entire aggregate principal amount of $16.3 million remained outstanding under the New Mudrick Notes, which became due and payable in full on October 31, 2023. Our available cash and other liquid assets are currently not sufficient to pay such obligations in full. If we do not pay the New Mudrick Notes in full on the scheduled maturity date, Mudrick will have available to them all rights under the New Mudrick Loan Agreements and applicable law, which include, without limitation, foreclosing on the collateral securing the New Mudrick Notes. Mudrick’s exercise of any such rights could have a material adverse effect on our financial condition.

We are dependent on a small number of customers for a large percentage of our revenue.

We have a concentration in the volume of business we transacted with customers, as during the nine months ended September 30, 2023, two of our customers represented about 28% and 24% of our revenue, respectively, while during nine months ended September 30, 2022, two customers represented about 55% and 23%, respectively, of our revenue. At September 30, 2023, accounts receivable from two of our customers represented about 12% and 12%, respectively, of our gross accounts receivable, while at December 31, 2022, accounts receivable from our three largest customers represented about 23%, 16% and 10%, respectively, of our gross accounts receivable. The loss of any of these large customers would have a material adverse impact on our financial results.

Our failure to meet the continued listing requirements of the Nasdaq Stock Market could result in a delisting of our common stock.

On April 27, 2023, we received a written notice from the Nasdaq Listing Qualifications Department notifying us that, pursuant to Nasdaq Listing Rule 5550(b)(3), we are required to maintain a minimum of $500,000 in net income from continuing operations in the most recently completed fiscal year, or two of the last three fiscal years (the “Net Income Standard”). Since our 2022 Form 10-K reported net loss from continuing operations, and as of April 25, 2023, we did not meet the alternative continued listing standards (collectively, with the Net Income Standard, the “Continued Listing Standards”) under Nasdaq Listing Rule 5550(b) of a minimum stockholders' equity of $2.5 million or minimum market value of listed securities of $35 million, we no longer comply with the Continued Listing Standards. In accordance with Nasdaq Listing Rule 5810(c)(2)(A), on June 12, 2023 we submitted a plan to regain compliance with the Continued Listing Standards to the Nasdaq Listing Qualifications Department. On July 24, 2023, the Nasdaq Listing Qualifications Department notified us that it was granting us until October 24, 2023 (the “Extension Period”) to file a report with the SEC and Nasdaq stating that we have successfully executed our plan to regain compliance with the Continued Listing Standards and that we did in fact regain such compliance. We were not able to regain compliance with the Continued Listing Standards by October 24, 2023 and, on October 26, 2023, we received a staff determination letter from Nasdaq indicating that we did not regain compliance with the Continued Listing Standards and that, unless we request an appeal of Nasdaq’s determination, our common stock was subject to delisting.

We appealed Nasdaq’s delisting determination to a Hearings Panel (the “Panel”) and were notified by Nasdaq that we have been granted a hearing with the Panel on February 1, 2024.

Our failure to meet the continued listing requirements in the future could result in a delisting of our common stock. A delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, customers and employees and potential loss of business development opportunities. A delisting from Nasdaq could adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly impact the ability of investors to trade our securities and would negatively impact the value and liquidity of our common stock.


Table of Contents			41

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES

We did not sell any equity securities during the quarter ended September 30, 2023 in transactions that were not registered under the Securities Act other than as previously disclosed in our filings with the SEC and as described below.

Between July 1, 2023 and September 30, 2023, we issued 2,702,589 shares of common stock to Ionic Ventures, LLC for advances made pursuant to the ELOC Purchase Agreement between July 1, 2023 and September 30, 2023, we issued 300,000 shares of our common stock to Ionic Ventures, LLC to fulfil our obligations as a result of our failure to meet the filing and effectiveness deadlines specified in the Registration Rights Agreement, and we issued 97,000 shares of our common stock to Ionic Ventures, LLC in partial fulfillment of our obligations pursuant to the 2023 Debentures.

We made the offer and sale of securities in the above-described private placement in reliance upon an exemption from registration requirements pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, based upon representations made to us by the investor in a purchase agreement we entered into with the investor.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION


Table of Contents			42

ITEM 6. EXHIBITS

Incorporated Herein
By Reference To

Exhibit Number

Description

Document

File Number

Filed On

Exhibit Number

3.1

Amended and Restated Certificate of Incorporation

8-K

001-33720

12/30/2014

3.1

3.2

Certificate of Amendment to the Amended and Restated Certificate of Incorporation

8-K

001-33720

01/12/2016

3.1

3.3

Certificate of Amendment to the Amended and Restated Certificate of Incorporation

8-K

001-33720

06/08/2016

3.1

3.4

Certificate of Amendment to the Amended and Restated Certificate of Incorporation

8-K

001-33720

04/11/2017

3.1

3.5

Certificate of Amendment to the Amended and Restated Certificate of Incorporation

8-K

001-33720

07/09/2021

3.1

3.6

Certificate of Amendment to the Amended and Restated Certificate of Incorporation

8-K

001-33720

12/21/2022

3.1

3.7

Amended and Restated Bylaws

8-K

001-33720

02/13/2015

3.1

10.1

Letter Agreement, dated as of July 12, 2023, by and between Remark Holdings, Inc. and Ionic Ventures, LLC

8-K

001-33720

07/18/2023

10.1

10.2

Letter Agreement, dated as of August 10, 2023, by and between Remark Holdings, Inc. and Ionic Ventures, LLC

8-K

001-33720

08/16/2023

10.1

10.3

Letter Agreement, dated as of September 15, 2023, by and between Remark Holdings, Inc. and Ionic Ventures, LLC

8-K

001-33720

09/21/2023

10.1

10.4*

Letter Agreement, dated as of November 18, 2023, by and between Remark Holdings, Inc. and Ionic Ventures, LLC

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

101.INS*

Inline XBRL Instance Document

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document


Table of Contents			43

Incorporated Herein
By Reference To

Exhibit Number

Description

Document

File Number

Filed On

Exhibit Number

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

XBRL Taxonomy Extension Presentation Linkbase Document

104*

The cover page from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL (included as Exhibit 101).

* Filed herewith


Table of Contents			44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

REMARK HOLDINGS, INC.

Date:

November 20, 2023

By:

/s/ Kai-Shing Tao

Kai-Shing Tao

Chairman and Chief Executive Officer

(principal executive, financial and accounting officer)


Table of Contents			45

EXHIBIT 10.1

November 18, 2023

Ionic Ventures, LLC

3053 Fillmore St., Suite 256

San Francisco, CA 94123

Re: Side Letter to Subordinated Convertible Debenture

Dear Sirs:

Reference Reference is made to that certain Subordinated Convertible Debenture, dated as of March 14, 2023, issued by Remark Holdings, Inc. (the “Company”) in favor of Ionic Ventures, LLC or its registered assigns (the “Holder”), in an original aggregate principal amount of $1,667,000 (such debenture, the “Original Debenture”) and our previous agreement and understanding that the Original Debenture would be modified in accordance with a certain separate letter agreement dated September 15, 2023, which memorialized the previously agreed to amendments. The purpose of this letter agreement (this “Letter Agreement”) is simply to memorialize the terms below, which have previously been agreed to and disclosed in an 8-K filed with the Securities and Exchange Commission on or about September 21, 2023.

Pursuant to this Letter Agreement, the parties hereto codify the previous agreement as follows:

1.Section 9(a) of the Original Debenture is hereby deleted in its entirety and replaced by the following:

(a)Reservation. So long as this Debenture remains outstanding, the Company shall at all times reserve at least 150% of the number of Common Shares, and as of the Effective Date, no less than 50,000,000 Common Shares, as shall from time to time be necessary to effect the conversion of this Debenture then outstanding (without regard to any limitations on conversions and assuming this Debenture remains outstanding until the Maturity Date) (the “Required Reserve Amount”).

2.Section 10 of the Original Debenture is hereby deleted in its entirety and replaced by the following:

10. MOST FAVORED NATION. If, while this Debenture is outstanding, the Company (i) issues other indebtedness of the Company (“New Debt”) or (ii) modifies the terms of indebtedness of the Company existing on November 8, 2023 (“Existing Debt” and, together with New Debt, the “Other Debt”), then the Company will provide the Holder with written notice thereof, together with a copy of all other documentation relating to such Other Debt. The Company will provide such notice to Holder promptly following the issuance of such Other Debt. In the event Holder determines that the terms or conditions of such Other Debt are preferable to the terms or conditions of this Debenture, Holder will notify the Company in writing within five (5) days following Holder’s receipt of such notice from the Company; provided, however, that no failure on the part of the Holder to provide such written notification will operate as a waiver of such Holder’s rights under this Section 10. Promptly after receipt of such written notice from Holder, but in any event within five (5) calendar days, the Company will amend and restate this Debenture so as to give such Holder the benefit of such more preferable terms or conditions, excluding the Principal and Interest; provided, further, however, that in the event that the Company shall fail to amend and restate this Debenture, the Holder shall still enjoy all such rights under the modified Debenture as if the Company had properly provided such amended and restated Debenture as called for in this Section 10.

This Letter Agreement (a) shall be governed by and construed in accordance with the law of the State of Delaware, (b) is for the exclusive benefit of the parties hereto, (c) may be modified, waived or assigned only in

writing and only to the extent such modification, waiver or assignment would be permitted under the Original Debenture (and any attempt to assign this Letter Agreement without such writing shall be null and void), (d) is a negotiated document, entered into freely among the parties upon advice of their own counsel, and it should not be construed against any of its drafters and (e) shall survive the satisfaction or discharge of the amounts owing under the Original Debenture. The fact that any term or provision of this Letter Agreement is held invalid, illegal or unenforceable as to any person in any situation in any jurisdiction shall not affect the validity, enforceability or legality of the remaining terms or provisions hereof or the validity, enforceability or legality of such offending term or provision in any other situation or jurisdiction or as applied to any person.

This Letter Agreement is expressly conditioned on (a) the Company’s Board of Directors approving this Letter Agreement and all undertakings thereto in all respects and providing written evidence of the same to the Holder by November 18, 2023 and (b) the Company agreeing that it shall, within the time required under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), file with the Securities and Exchange Commission a Current Report on Form 8-K relating to the amendments contained in this Letter Agreement; provided, however, that at the reasonable request of the Holder, the Company will use commercially reasonable efforts to file such Current Report on Form 8-K prior to the time required under Exchange Act. The parties agree that this letter merely memorializes the parties’ prior agreement and understanding and that sufficient consideration was previously paid and received.

Very truly yours,

REMARK HOLDINGS, INC.

By:

/s/ Kai-Shing Tao

Name:

Kai-Shing Tao

Title:

Chief Executive Officer

AGREED AND ACCEPTED:

IONIC VENTURES, LLC

By:

/s/ Brendan O'Neil

Name:

Brendan O'Neil

Title:

Authorized Signatory

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kai-Shing Tao (the registrant's principal executive officer), certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Remark Holdings, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 20, 2023


By:			/s/ Kai-Shing Tao
			Kai-Shing Tao
			Chief Executive Officer and Chairman

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kai-Shing Tao (the registrant's principal financial officer and principal accounting officer), certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Remark Holdings, Inc.;

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 20, 2023


By			/s/ Kai-Shing Tao
			Kai-Shing Tao
			Chief Executive Officer and Chairman

EXHIBIT 32

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Kai-Shing Tao, the registrant's principal executive, financial and accounting officer, certify that, to my knowledge:

1.the accompanying Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Remark Holdings, Inc. at the dates and for the periods indicated.

Date: November 20, 2023


			/s/ Kai-Shing Tao
			Kai-Shing Tao
			Chief Executive Officer and Chairman

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2023	Nov. 17, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-33720
Entity Registrant Name	Remark Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1135689
Entity Address, Address Line One	800 S. Commerce St.
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89106
City Area Code	702
Local Phone Number	701-9514
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	MARK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,931,855
Entity Central Index Key	0001368365
Current Fiscal year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets
Cash	$ 270	$ 52
Trade accounts receivable, net	3,043	3,091
Inventory, net	455	308
Deferred cost of revenue	5,899	7,463
Prepaid expense and other current assets	801	1,374
Total current assets	10,468	12,288
Property and equipment, net	1,106	1,699
Operating lease assets	678	180
Other long-term assets	146	269
Total assets	12,398	14,436
Liabilities
Obligations to issue common stock	9,184	1,892
Accrued expense and other current liabilities	9,353	7,222
Contract liability	363	308
Notes payable (past due)	16,472	14,607
Total current liabilities	44,980	34,805
Operating lease liabilities, long-term	336	56
Total liabilities	45,316	34,861
Commitments and contingencies
Stockholders’ Deficit
Preferred stock, $0.001 par value; 1,000,000 shares authorized; zero issued	0	0
Common stock, $0.001 par value; 175,000,000 shares authorized; 19,711,855 and 11,539,564 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	20	12
Additional paid-in-capital	378,022	368,945
Accumulated other comprehensive loss	(1,229)	(859)
Accumulated deficit	(409,731)	(388,523)
Total stockholders’ deficit	(32,918)	(20,425)
Total liabilities and stockholders’ deficit	12,398	14,436
Nonrelated Party
Liabilities
Accounts payable	8,578	9,602
Related Party
Liabilities
Accounts payable	$ 1,030	$ 1,174

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares, issued (in shares)	19,711,855	11,539,564
Common stock, shares, outstanding (in shares)	19,711,855	11,539,564

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue, including amounts from China Business Partner (See Note 15)	$ 183	$ 2,812	$ 4,176	$ 10,037
Cost and expense
Cost of revenue (excluding depreciation and amortization)	254	2,459	3,220	8,576
Sales and marketing	340	270	1,093	606
Technology and development	768	41	1,504	1,004
General and administrative	2,843	6,726	8,920	14,598
Depreciation and amortization	107	43	178	121
Impairments	0	0	392	0
Total cost and expense	4,312	9,539	15,307	24,905
Operating loss	(4,129)	(6,727)	(11,131)	(14,868)
Other income (expense)
Interest expense	(949)	(1,365)	(3,351)	(5,325)
Finance cost related to obligations to issue common stock	(2,086)	0	(6,712)	0
Loss on investment	0	(348)	0	(26,356)
Other gain, net	(8)	(493)	(14)	(342)
Total other expense, net	(3,043)	(2,206)	(10,077)	(32,023)
Loss before income taxes	(7,172)	(8,933)	(21,208)	(46,891)
Provision for income taxes	0	9	0	9
Net loss	(7,172)	(8,924)	(21,208)	(46,882)
Other comprehensive income
Foreign currency translation adjustments	175	(445)	(370)	(867)
Comprehensive loss	$ (6,997)	$ (9,369)	$ (21,578)	$ (47,749)
Weighted-average shares outstanding, basic (in shares)	18,377,384	10,529,055	15,355,583	10,529,055
Weighted-average shares outstanding, diluted (in shares)	18,377,384	10,529,055	15,355,583	10,529,055
Net loss per share, basic (in dollars per share)	$ (0.39)	$ (0.85)	$ (1.38)	$ (4.45)
Net loss per share, diluted (in dollars per share)	$ (0.39)	$ (0.85)	$ (1.38)	$ (4.45)

Unaudited Condensed Consolidated Statements of Stockholders’ Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		10,515,777
Beginning balance at Dec. 31, 2021	$ 31,034	$ 11	$ 364,333	$ (270)	$ (333,040)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(46,882)				(46,882)
Share-based compensation	1,525		1,525
Common stock issued for services (in shares)		125,000
Common stock issued for services	500	$ 1	499
Foreign currency translation	(867)			(867)
Ending balance (in shares) at Sep. 30, 2022		10,640,777
Ending balance at Sep. 30, 2022	(14,690)	$ 12	366,357	(1,137)	(379,922)
Beginning balance (in shares) at Jun. 30, 2022		10,515,777
Beginning balance at Jun. 30, 2022	(6,322)	$ 11	365,357	(692)	(370,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,924)				(8,924)
Share-based compensation	501		501
Common stock issued for services (in shares)		125,000
Common stock issued for services	500	$ 1	499
Foreign currency translation	(445)			(445)
Ending balance (in shares) at Sep. 30, 2022		10,640,777
Ending balance at Sep. 30, 2022	$ (14,690)	$ 12	366,357	(1,137)	(379,922)
Beginning balance (in shares) at Dec. 31, 2022	11,539,564	11,539,564
Beginning balance at Dec. 31, 2022	$ (20,425)	$ 12	368,945	(859)	(388,523)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(21,208)				(21,208)
Share-based compensation	167		167
Common stock issued pursuant to agreements with Ionic (Note 11) (in shares)		8,172,291
Common stock issued pursuant to agreements with Ionic (Note 11)	8,918	$ 8	8,910
Foreign currency translation	$ (370)			(370)
Ending balance (in shares) at Sep. 30, 2023	19,711,855	19,711,855
Ending balance at Sep. 30, 2023	$ (32,918)	$ 20	378,022	(1,229)	(409,731)
Beginning balance (in shares) at Jun. 30, 2023		16,612,266
Beginning balance at Jun. 30, 2023	(28,429)	$ 17	375,517	(1,404)	(402,559)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,172)				(7,172)
Share-based compensation	11		11
Common stock issued pursuant to agreements with Ionic (Note 11) (in shares)		3,099,589
Common stock issued pursuant to agreements with Ionic (Note 11)	2,497	$ 3	2,494
Foreign currency translation	$ 175			175
Ending balance (in shares) at Sep. 30, 2023	19,711,855	19,711,855
Ending balance at Sep. 30, 2023	$ (32,918)	$ 20	$ 378,022	$ (1,229)	$ (409,731)

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (7,172)	$ (8,924)	$ (21,208)	$ (46,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			178	121
Share-based compensation			149	1,185
Amortization of debt issuance costs and discount			0	2,189
Cost of extending note payable			750	0
Finance cost related to obligations to issue common stock			6,712	0
Accrued interest included in note payable			1,139	283
Stock issuance for services performed			0	500
Loss on investment	0	348	0	26,356
Impairment of assets	0	0	392	0
Provision for doubtful accounts			138	2,278
Other			224	(178)
Changes in operating assets and liabilities:
Accounts receivable			(593)	1,298
Inventory			83	(209)
Deferred cost of revenue			1,564	(5,041)
Prepaid expense and other assets			85	3,815
Operating lease assets			(503)	63
Accounts payable, accrued expense and other liabilities			1,437	826
Contract liability			90	(245)
Operating lease liabilities			280	6
Net cash used in operating activities			(9,083)	(13,635)
Cash flows from investing activities:
Proceeds from sale of investment			0	6,332
Purchases of property, equipment and software			(32)	(175)
Payment of amounts capitalized to software in progress			0	(999)
Net cash provided by (used in) investing activities			(32)	5,158
Cash flows from financing activities:
Proceeds from issuance of common stock, net			0	0
Proceeds from obligations to issue common stock - ELOC			7,000	0
Proceeds from obligations to issue common stock - Debentures			2,500	0
Advances from related parties			1,002	2,386
Repayments of advances from related parties			(1,145)	(1,517)
Repayments of debt			(24)	(6,203)
Net cash provided by (used in) financing activities			9,333	(5,334)
Net change in cash			218	(13,811)
Cash:
Beginning of period			52	14,187	$ 14,187
End of period	$ 270	$ 376	270	376	$ 52
Supplemental cash flow information:
Cash paid for interest			1,578	3,238
Supplemental schedule of non-cash investing and financing activities:
Transfer of marketable securities to partially settle notes payable			0	9,661
Finance fee			0	283
Issuance of common stock pursuant to equity line of credit			8,910	0
Transfer of software to inventory			$ 233	$ 0

ORGANIZATION AND BUSINESS	9 Months Ended
ORGANIZATION AND BUSINESS	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS	NOTE 1. ORGANIZATION AND BUSINESS Organization and Business Remark Holdings, Inc. and its subsidiaries (“Remark”, “we”, “us”, or “our”) constitute a diversified global technology business with leading artificial intelligence (“AI”) and data-analytics solutions. The common stock of Remark Holdings, Inc. is listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol MARK. We primarily sell AI-based products and services. We currently recognize substantially all of our revenue from China, with additional revenue from sales in the U.S. On December 21, 2022, we effected a 1-for-10 reverse split of our common stock (the “Reverse Split”). All references made to share or per share amounts in these financial statements have been retroactively adjusted to reflect the effects of the Reverse Split. Corporate Structure We are a holding company incorporated in Delaware and not a Chinese operating company. As a holding company, we conduct most of our operations through our subsidiaries, each of which is wholly owned. Until September 2022, we had historically conducted a significant part of our operations through contractual arrangements between our wholly-foreign-owned enterprise (“WFOE”) and certain variable interest entities (“VIEs”) based in China to address challenges resulting from laws, policies and practices that may disfavor foreign-owned entities that operate within industries deemed sensitive by the Chinese government. We were the primary beneficiary of the VIEs because the contractual arrangements governing the relationship between the VIEs and our WFOE, which included an exclusive call option agreement, exclusive business cooperation agreement, a proxy agreement and an equity pledge agreement, enabled us to (i) exercise effective control over the VIEs, (ii) receive substantially all of the economic benefits of the VIEs, and (iii) have an exclusive call option to purchase, at any time, all or part of the equity interests in and/or assets of the VIEs to the extent permitted by Chinese laws. Because we were the primary beneficiary of the VIEs, we consolidated the financial results of the VIEs in our consolidated financial statements in accordance with generally accepted accounting principles (“GAAP”). We terminated all of the contractual arrangements between the WFOE and the VIEs and exercised our rights under the exclusive call option agreements between the WFOE and the VIEs such that, effective as of September 19, 2022, we obtained 100% of the equity ownership of the entities we formerly consolidated as VIEs and which we now consolidate as wholly-owned subsidiaries. The following diagram illustrates our corporate structure, including our significant subsidiaries, as of the date of this Form 10-Q. The diagram omits certain entities which are immaterial to our results of operations and financial condition. We are subject to certain legal and operational risks associated with having a significant portion of our operations in China. Chinese laws and regulations governing our current business operations, including the enforcement of such laws and regulations, are sometimes vague and uncertain and can change quickly with little advance notice. The Chinese government may intervene in or influence the operations of our China-based subsidiaries at any time and may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value of our securities. In addition, any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer our securities to investors and cause the value of such securities to significantly decline or become worthless. In recent years, the Chinese government adopted a series of regulatory actions and issued statements to regulate business operations in China, including those related to the use of variable interest entities, cybersecurity, data security, export control and anti-monopoly concerns. As of the date of this Form 10-Q, we have neither been involved in any investigations on cybersecurity review initiated by any Chinese regulatory authority, nor received any inquiry, notice or sanction. As of the date of this Form 10-Q, no relevant laws or regulations in China explicitly require us to seek approval from the China Securities Regulatory Commission (“CSRC”) for any securities listing. As of the date of this Form 10-Q, we have not received any inquiry, notice, warning or sanctions regarding our planned overseas listing from the CSRC or any other Chinese governmental authorities relating to securities listings. However, since these statements and regulatory actions are newly published, official guidance and related implementation rules have not all been issued. It is highly uncertain what potential impact such modified or new laws and regulations will have on our ability to conduct our business, accept investments or list or maintain a listing on a U.S. or foreign exchange. As of the date of this Form 10-Q, we are not required to seek permissions from the CSRC, the Cyberspace Administration of China (the “CAC”), or any other entity that is required to approve our operations in China. Nevertheless, Chinese regulatory authorities may in the future promulgate laws, regulations or implement rules that require us or our subsidiaries to obtain permissions from such regulatory authorities to approve our operations or any securities listing. Holding Foreign Companies Accountable Act The Holding Foreign Companies Accountable Act (the “HFCA Act”) was enacted on December 18, 2020. The HFCA Act states that if the Securities and Exchange Commission (the “SEC”) determines that a company has filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the Public Company Accounting Oversight Board (the “PCAOB”) for three consecutive years beginning in 2021, the SEC shall prohibit such shares from being traded on a national securities exchange or in the over the counter trading market in the United States. On December 2, 2021, the SEC adopted amendments to finalize rules implementing the submission and disclosure requirements in the HFCA Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB is unable to inspect or investigate completely because of a position taken by an authority in a foreign jurisdiction. The Consolidated Appropriations Act, 2023, which was signed into law on December 29, 2022, amended the HFCA Act to reduce the number of consecutive non-inspection years required to trigger the trading prohibition under the HFCA Act from three years to two years. On December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and in Hong Kong because of positions taken by Chinese and Hong Kong authorities in those jurisdictions. On August 26, 2022, the CSRC, the Ministry of Finance of the PRC, and the PCAOB signed a Statement of Protocol (the “Protocol”), taking the first step toward opening access for the PCAOB to completely inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. On December 15, 2022, the PCAOB vacated its 2021 determination that the positions taken by authorities in mainland China and Hong Kong prevented it from inspecting and investigating completely registered public accounting firms headquartered in those jurisdictions. In view of the PCAOB’s decision to vacate its 2021 determination and until such time as the PCAOB issues any new adverse determination, the SEC has stated that there are no issuers at risk of having their securities subject to a trading prohibition under the HFCA Act. Each year, the PCAOB will reassess its determinations on whether it can inspect and investigate completely audit firms in China, and if, in the future, the PCAOB determines it cannot do so, or if Chinese authorities do not allow the PCAOB complete access for inspections and investigations for two consecutive years, companies engaging China-based public accounting firms would be delisted pursuant to the HFCA Act. Our auditor, Weinberg & Company, an independent registered public accounting firm headquartered in the United States is currently subject to PCAOB inspections and has been inspected by the PCAOB on a regular basis. However, if the PCAOB is unable to inspect the work papers of our accounting firm in the future, such lack of inspection could cause trading in our common stock to be prohibited under the HFCA Act, and as a result, an exchange may determine to delist our common stock. The delisting and the cessation of trading of our common stock, or the threat of our common stock being delisted and prohibited from being traded, may materially and adversely affect the value of our common stock. Transfer of Cash or Assets Dividend Distributions As of the date of this Form 10-Q, none of our subsidiaries have made any dividends or distributions to Remark. We have never declared or paid dividends or distributions on our common equity. We currently intend to retain all available funds and any future consolidated earnings to fund our operations and continue the development and growth of our business; therefore, we do not anticipate paying any cash dividends. Under Delaware law, a Delaware corporation’s ability to pay cash dividends on its capital stock requires the corporation to have either net profits or positive net assets (total assets less total liabilities) over its capital. If we determine to pay dividends on any of our common stock in the future, as a holding company, we may rely on dividends and other distributions on equity from our subsidiaries for cash requirements, including the funds necessary to pay dividends and other cash contributions to our stockholders. Our WFOE’s ability to distribute dividends is based upon its distributable earnings. Current Chinese regulations permit our WFOE to pay dividends to its shareholder only out of its registered capital amount, if any, as determined in accordance with Chinese accounting standards and regulations, and then only after meeting the requirement regarding statutory reserve. If our WFOE incurs debt in the future, the instruments governing the debt may restrict its ability to pay dividends or make other payments to us. Any limitation on the ability of our WFOE to distribute dividends or other payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our businesses, pay dividends or otherwise fund and conduct our business. In addition, any cash dividends or distributions of assets by our WFOE to its stockholder are subject to a Chinese withholding tax of as much as 10%. The Chinese government also imposes controls on the conversion of Chinese Renminbi (“RMB”) into foreign currencies and the remittance of currencies out of China. Therefore, we may experience difficulties in completing the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from our profits, if any. If we are unable to receive all of the revenues from our operations through our China-based subsidiaries, we may be unable to pay dividends on our common stock. COVID-19 Our condensed consolidated financial statements for the nine months ended September 30, 2023 continued to show the negative impact that the COVID-19 pandemic has had on our business. Preventative measures related to COVID-19 outbreaks may continue to adversely affect our business and financial results, as could economic and geopolitical conditions in some international regions, and we do not yet know what will be the ultimate effects on our business. The COVID-19 pandemic caused a broad shift towards remote working arrangements for many businesses worldwide and injected uncertainty and delay into decision-making processes for such businesses. Though the most restrictive preventative measures have been eased in China, city-wide lockdowns, travel restrictions, closures of non-essential businesses and other quarantine measures could be reinstituted at any time. Recovering from the effects of the preventative measures in China that resulted from the Chinese government’s Zero-COVID policy and that significantly limited the operational capabilities of our China-based subsidiaries has been a slow process. Though the weeks-long or months-long lockdowns instituted in many cities across large swaths of China, including economically significant regions such as Shanghai, were lifted as of the end of 2022, they have had a material adverse impact on our business, including on the collection of our accounts receivable and our ability to complete projects in China to generate revenue, and may continue to adversely impact our business until customers and potential customers believe they can operate and expand their businesses without fear of lockdowns or other severely restrictive preventative measures. The full extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including resurgences and further spread of existing or new COVID-19 variants, the duration of any remaining preventative measures implemented by domestic and foreign governments, the impact on capital and financial markets and the related impact on the financial circumstances of our customers, all of which are highly uncertain and cannot be predicted. The COVID-19 situation has historically changed rapidly, and additional impacts of which we are not currently aware may arise. We are closely monitoring worldwide developments and continually assess the potential impact on our business. Going Concern During the nine months ended September 30, 2023, and in each fiscal year since our inception, we have incurred operating losses which have resulted in a stockholders’ deficit of $32.9 million as of September 30, 2023. Additionally, our operations have historically used more cash than they have provided. Net cash used in operating activities was $9.1 million during the nine months ended September 30, 2023. As of September 30, 2023, our cash balance was $0.3 million. Also, we did not make required repayments of the outstanding loans under the New Mudrick Loan Agreement when due (see Note 10 for more information). Our history of recurring operating losses, working capital deficiencies and negative cash flows from operating activities give rise to, and management has concluded that there is, substantial doubt regarding our ability to continue as a going concern. Our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December 31, 2022, has also expressed substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We intend to fund our future operations and meet our financial obligations through revenue growth from our AI and data analytics offerings. We cannot, however, provide assurance that revenue, income and cash flows generated from our businesses will be sufficient to sustain our operations in the twelve months following the filing of this Form 10-Q. As a result, we are actively evaluating strategic alternatives including debt and equity financings. Conditions in the debt and equity markets, as well as the volatility of investor sentiment regarding macroeconomic and microeconomic conditions (in particular, as a result of the COVID-19 pandemic, global supply chain disruptions, inflation and other cost increases, and the geopolitical conflict in Ukraine), will play primary roles in determining whether we can successfully obtain additional capital. We cannot be certain that we will be successful at raising additional capital. A variety of factors, many of which are outside of our control, affect our cash flow; those factors include the effects of the COVID-19 pandemic, regulatory issues, competition, financial markets and other general business conditions. Based on financial projections, we believe that we will be able to meet our ongoing requirements for at least the next 12 months with existing cash and based on the probable success of one or more of the following plans: •develop and grow new product line(s) •obtain additional capital through debt and/or equity issuances. However, projections are inherently uncertain and the success of our plans is largely outside of our control. As a result, there is substantial doubt regarding our ability to continue as a going concern, and we may fully utilize our cash resources prior to December 31, 2023.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Consolidation

We include all of our subsidiaries in our condensed consolidated financial statements, eliminating all significant intercompany balances and transactions during consolidation.

Use of Estimates

Cash

Our cash consists of funds held in bank accounts.




	September 30, 2023		December 31, 2022
Cash denominated in:
USD	$	250	$	11
RMB	13		19
GBP	3		17
HKD	4		5
Total cash	$	270	$	52

Fair Value of Financial Instruments

Level 1: Valuations based on quoted prices in active markets for identical assets and liabilities;

Level 3: Valuations based on unobservable inputs, which are based upon the best available information when external market data is limited or unavailable.

Foreign Currency Translation

We used the exchange rates in the following table to translate amounts denominated in non-USD currencies as of and for the periods noted:


	2023	2022
Exchange rates at September 30th:
GBP:USD	1.220	1.113
RMB:USD	0.137	0.141
HKD:USD	0.128	0.127

Average exchange rate during the nine months ended September 30th:
RMB:USD	0.142	0.152
GBP:USD	1.244	1.259

Revenue Recognition

AI-Based Products

For contracts under which we have not yet completed the performance obligation, deferred costs are recorded for any amounts incurred in advance of the performance obligation.

For our contracts with customers, we generally extend short-term credit policies to our customers, typically up to one year for large-scale projects.

We record the incremental costs of obtaining contracts as an expense when incurred.

We offer extended warranties on our products for periods of one to three years. Revenue from these extended warranties is recognized on a straight-line basis over the warranty contract term.

Other

Inventory

Refundable Tax Credits

Internal Use Software

Net Income (Loss) per Share

Segments

Recently Issued Accounting Pronouncements

CONCENTRATION OF RISK	9 Months Ended
CONCENTRATION OF RISK	Sep. 30, 2023
Risks and Uncertainties [Abstract]
CONCENTRATION OF RISK	NOTE 3. CONCENTRATION OF RISK Revenue and Accounts Receivable The disaggregation of revenue tables in Note 4 demonstrate the concentration in our revenue from certain products and the geographic concentration of our business. We also have a concentration in the volume of business we transacted with customers, as during the nine months ended September 30, 2023, two of our customers represented about 28% and 24% of our revenue, respectively, while during nine months ended September 30, 2022, two customers represented about 55% and 23%, respectively, of our revenue. At September 30, 2023, accounts receivable from two of our customers represented about 12% an 12%, respectively, of our gross accounts receivable, while at December 31, 2022, accounts receivable from our three largest customers represented about 23%, 16% and 10%, respectively, of our gross accounts receivable. Deferred Cost of Revenue See Note 6 for a discussion of a risk concentration regarding our deferred cost of revenue. Cost of Sales and Accounts Payable The various hardware we purchase to fulfill our contracts with customers is not especially unique in nature. Based on our analysis, we believe that should any disruption in our current supply chain occur, a sufficient number of alternative vendors is available to us, at reasonably comparable specifications and price, such that we would not experience a material negative impact on our ability to procure the hardware we need to operate our business.

REVENUE

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

REVENUE

NOTE 4. REVENUE

We primarily sell AI-based products and services based upon computer vision and other technologies.

Disaggregation of Revenue

The following table presents a disaggregation of our revenue by category of products and services (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
AI-based products and services, including amounts from China Business Partner in 2023 (See Note 15)	$	174	$	2,681	$	4,000	$	9,699
Other	9		131		176		338
Revenue	$	183	$	2,812	$	4,176	$	10,037

The following table presents a disaggregation of our revenue by country (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
China	$	174	$	2,746	$	4,014	$	9,815
United States and United Kingdom	9		66		162		222

Revenue	$	183	$	2,812	$	4,176	$	10,037

Significant Judgments

Contract Assets and Contract Liabilities

We do not currently generate material contract assets. During the nine months ended September 30, 2023, our contract liability changed only as a result of routine business activity.

During the nine months ended September 30, 2023 and 2022, the amount of revenue we recognized that was included in the beginning balance of Contract liability was not material.

During the nine months ended September 30, 2023 and 2022, we did not recognize revenue from performance obligations that were satisfied in previous periods.

Certain Agreements Related to AI-Based Product Sales in China

We completed certain projects in China during the three months ended September 30, 2023 worth approximately $1.4 million, but the agreement has not yet met the criteria for revenue recognition.

NOTE 6. DEFERRED COST OF REVENUE

TRADE ACCOUNTS RECEIVABLE

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

TRADE ACCOUNTS RECEIVABLE

NOTE 5. TRADE ACCOUNTS RECEIVABLE




	September 30, 2023		December 31, 2022
Gross accounts receivable balance	$	7,103	$	7,213
Allowance for bad debt	(4,060)		(4,122)
Accounts receivable, net	$	3,043	$	3,091

DEFERRED COST OF REVENUE

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

DEFERRED COST OF REVENUE

NOTE 4. REVENUE

We primarily sell AI-based products and services based upon computer vision and other technologies.

Disaggregation of Revenue

The following table presents a disaggregation of our revenue by category of products and services (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
AI-based products and services, including amounts from China Business Partner in 2023 (See Note 15)	$	174	$	2,681	$	4,000	$	9,699
Other	9		131		176		338
Revenue	$	183	$	2,812	$	4,176	$	10,037

The following table presents a disaggregation of our revenue by country (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
China	$	174	$	2,746	$	4,014	$	9,815
United States and United Kingdom	9		66		162		222

Revenue	$	183	$	2,812	$	4,176	$	10,037

Significant Judgments

Contract Assets and Contract Liabilities

We do not currently generate material contract assets. During the nine months ended September 30, 2023, our contract liability changed only as a result of routine business activity.

During the nine months ended September 30, 2023 and 2022, the amount of revenue we recognized that was included in the beginning balance of Contract liability was not material.

During the nine months ended September 30, 2023 and 2022, we did not recognize revenue from performance obligations that were satisfied in previous periods.

Certain Agreements Related to AI-Based Product Sales in China

We completed certain projects in China during the three months ended September 30, 2023 worth approximately $1.4 million, but the agreement has not yet met the criteria for revenue recognition.

NOTE 6. DEFERRED COST OF REVENUE

PREPAID EXPENSE AND OTHER CURRENT ASSETS

9 Months Ended

Sep. 30, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

PREPAID EXPENSE AND OTHER CURRENT ASSETS

NOTE 7. PREPAID EXPENSE AND OTHER CURRENT ASSETS

The following table presents the components of prepaid expense and other current assets (in thousands):




	September 30, 2023		December 31, 2022


Other receivables	2		23
Prepaid expense	547		1,144
Deposits	245		201

Other current assets	7		6
Total	$	801	$	1,374

During the nine months ended September 30, 2023, we recorded an impairment of approximately $0.2 million related to certain prepaid expense amounts which were deemed unrecoverable.

PROPERTY AND EQUIPMENT

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 8. PROPERTY AND EQUIPMENT

Property and equipment consist of the following (in thousands, except estimated lives):




	Estimated Life (Years)	September 30, 2023		December 31, 2022
Vehicles	3	$	153	153
Computers and equipment	3	1,193		$	1,170
Furniture and fixtures	3	42		42
Software	3	5,819		5,160
Leasehold improvements	3	206		204
Software development in progress		—		1,199
Total property, equipment and software		$	7,413	$	7,928
Less accumulated depreciation		(6,307)		(6,229)
Total property, equipment and software, net		$	1,106	$	1,699

ACCRUED EXPENSE AND OTHER CURRENT LIABILITIES

9 Months Ended

Sep. 30, 2023

Other Liabilities Disclosure [Abstract]

ACCRUED EXPENSE AND OTHER CURRENT LIABILITIES

NOTE 9. ACCRUED EXPENSE AND OTHER CURRENT LIABILITIES

The following table presents the components of Accrued expense and other current liabilities (in thousands):




	September 30, 2023		December 31, 2022
Accrued compensation and benefit-related expense	$	2,822	$	1,448
Accrued interest	633		769
Other accrued expense	3,302		2,393
Other payables	2,018		2,234
Operating lease liability - current	367		138
China Cash Bonuses (see Note 15)	14		32
Other current liabilities	197		208
Total	$	9,353	$	7,222

NOTES PAYABLE (PAST DUE)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

NOTES PAYABLE (PAST DUE)

NOTE 10. NOTES PAYABLE (PAST DUE)

The following table presents our notes payable (in thousands) as of:




	September 30, 2023		December 31, 2022
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)	$	16,307	$	14,418
Other notes payable	165		189
Notes payable, net of unamortized discount and debt issuance cost	$	16,472	$	14,607

Other Notes Payable

NOTE 11. OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC)

Convertible Debentures

Equity Line of Credit

Accounting for the Debentures and the ELOC


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Obligations to Issue Common Stock
Balance at December 31, 2022	$	1,892	$	—	$	—	$	—	$	—	$	1,892
Establishment of new obligation to issue shares	—		4,109		332		249		10,483		15,173
Issuance of Shares	(3,138)		(94)		(294)		(227)		(5,167)		(8,920)
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Balance at September 30, 2023	$	—	$	4,673	$	—	$	—	$	4,511	$	9,184

Estimated Number of Shares Issuable
Balance at December 31, 2022	1,720,349		—		—		—		—		1,720,349
Establishment of new obligation to issue shares	—		3,669,228		300,000		200,715		11,326,803		15,496,746
Issuance of Shares	(2,230,814)		(97,000)		(300,000)		(200,715)		(5,343,762)		(8,172,291)
Change in estimated number of shares issuable	510,465		5,801,229		—		—		3,063,789		9,375,483
Balance at September 30, 2023	—		9,373,457		—		—		9,046,830		18,420,287

The following table shows the composition of finance cost associated with our obligations to issue common stock (dollars in thousands):


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Initial obligation in excess of purchase price	$	—	$	1,609	$	332	$	249	$	3,483	$	5,673
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Total	$	1,246	$	2,267	$	294	$	227	$	2,678	$	6,712

OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC)

NOTE 10. NOTES PAYABLE (PAST DUE)

The following table presents our notes payable (in thousands) as of:




	September 30, 2023		December 31, 2022
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)	$	16,307	$	14,418
Other notes payable	165		189
Notes payable, net of unamortized discount and debt issuance cost	$	16,472	$	14,607

Other Notes Payable

NOTE 11. OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC)

Convertible Debentures

Equity Line of Credit

Accounting for the Debentures and the ELOC


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Obligations to Issue Common Stock
Balance at December 31, 2022	$	1,892	$	—	$	—	$	—	$	—	$	1,892
Establishment of new obligation to issue shares	—		4,109		332		249		10,483		15,173
Issuance of Shares	(3,138)		(94)		(294)		(227)		(5,167)		(8,920)
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Balance at September 30, 2023	$	—	$	4,673	$	—	$	—	$	4,511	$	9,184

Estimated Number of Shares Issuable
Balance at December 31, 2022	1,720,349		—		—		—		—		1,720,349
Establishment of new obligation to issue shares	—		3,669,228		300,000		200,715		11,326,803		15,496,746
Issuance of Shares	(2,230,814)		(97,000)		(300,000)		(200,715)		(5,343,762)		(8,172,291)
Change in estimated number of shares issuable	510,465		5,801,229		—		—		3,063,789		9,375,483
Balance at September 30, 2023	—		9,373,457		—		—		9,046,830		18,420,287

The following table shows the composition of finance cost associated with our obligations to issue common stock (dollars in thousands):


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Initial obligation in excess of purchase price	$	—	$	1,609	$	332	$	249	$	3,483	$	5,673
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Total	$	1,246	$	2,267	$	294	$	227	$	2,678	$	6,712

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12. COMMITMENTS AND CONTINGENCIES At September 30, 2023, we had no material commitments outside the normal course of business. Contingencies As of September 30, 2023, we were neither a defendant in any material pending legal proceeding nor are we aware of any material threatened claims against us and, therefore, we have not accrued any contingent liabilities. Registration Rights Agreement On September 27, 2021, we entered into a securities purchase agreement (the “Armistice Purchase Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice Capital”) pursuant to which we issued shares of our common stock together with warrants to purchase our common stock, subject to certain customary anti-dilution adjustments (the “Armistice Warrants”). In connection with our entry into the Armistice Purchase Agreement, we also entered into a registration rights agreement with Armistice Capital, pursuant to which we were obligated to file one or more registration statements, as necessary, to register under the Securities Act of 1933, as amended, the resale of the shares we issued to Armistice Capital and the shares underlying the Armistice Warrants (collectively, the “Armistice Registrable Securities”) and to obtain effectiveness of such registration statement no later than 90 days following September 27, 2021. The registration rights agreement provided that if we failed to satisfy our obligation to timely obtain effectiveness, we would incur a penalty of as much as $1.0 million. The registration statement to register the resale of the Armistice Registrable Securities was declared effective on October 31, 2022. We had accrued the maximum penalty and, as of December 31, 2022, paid $0.2 million of such amount, resulting in an unpaid amount of $0.8 million included in other accrued expense as of September 30, 2023.

STOCKHOLDERS' DEFICIT

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' DEFICIT

NOTE 13. STOCKHOLDERS' DEFICIT

Warrants

The following table summarizes information related to our equity-classified stock warrant issuances as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	1,011,441	$	40.10	3.7	$	—
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	—	—
Outstanding at September 30, 2023	1,011,441	$	40.10	2.9	$	—

Share-Based Compensation

The following table summarizes activity under our equity incentive plans related to equity-classified stock option grants as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	1,626,631	$	30.31	5.5	$	1
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	(3,285)	46.75
Outstanding at September 30, 2023	1,623,346	$	30.28	5.0	$	—

Exercisable at December 31, 2022	1,549,681	31.41		5.3	$	1
Exercisable at September 30, 2023	1,601,649	30.79		4.6	$	—

The following table summarizes activity related to our liability-classified China Cash Bonuses as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	71,450	$	35.99	6.1	$	—
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	—	—
Outstanding at September 30, 2023	71,450	$	35.99	5.4	$	—

Exercisable at December 31, 2022	68,450	36.97		6.1	$	—
Exercisable at September 30, 2023	71,450	35.99		5.4	$	—

The following table presents the change in the liability associated with our China Cash Bonuses included in Accrued expense and other current liabilities (in thousands):


	Nine Months Ended September 30,		Year Ended December 31,
	2023		2022
Balance at beginning of period	$	32	$	439
Share-based compensation expense related to China Cash Bonuses	(18)		(407)
Balance at end of period	$	14	$	32

The following table presents a breakdown of share-based compensation cost included in operating expense (in thousands):


	Nine Months Ended September 30,
	2023		2022
Stock options	$	167	$	1,525
China Cash Bonuses	(18)		(340)
Total	$	149	$	1,185

The following table presents information regarding unrecognized share-based compensation cost associated with stock options and China Cash Bonuses:


			September 30, 2023
Unrecognized share-based compensation cost for non-vested awards (in thousands):
Stock options			31
China Cash Bonuses			—
Weighted-average years over which unrecognized share-based compensation expense will be recognized:
Stock options			1.4
China Cash Bonuses			0

RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 14. RELATED PARTY TRANSACTIONS As of September 30, 2023, we owed approximately $1.0 million to members of management representing various operating expense payments made on our behalf.

CHINA BUSINESS PARTNER	9 Months Ended
CHINA BUSINESS PARTNER	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
CHINA BUSINESS PARTNER	NOTE 15. CHINA BUSINESS PARTNER We interact with an unrelated entity (the “China Business Partner”) in more than one capacity. Firstly, since 2020, we have been working with the China Business Partner to earn revenue by obtaining business from some of the largest companies in China. Secondly, our artificial intelligence business in the U.S. has purchased substantially all of its inventory from a subsidiary of the China Business Partner which manufactures certain equipment to our specifications; though, during the nine months ended September 30, 2023, we did not make any such purchases. In addition, a member of our senior leadership team maintains a role in the senior management structure of the China Business Partner. During the nine months ended September 30, 2023 and 2022, we recognized approximately $0.1 million and $5.3 million, respectively, of revenue from the relationship with the China Business Partner. At September 30, 2023 and December 31, 2022, in addition to the outstanding accounts receivable balances from the China Business Partner described in Note 5, we had outstanding accounts payable to the China Business Partner of $0.7 million and $0.7 million, respectively.

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16. SUBSEQUENT EVENTS Ionic Transactions In November 2023, Ionic advanced to us approximately $0.6 million pursuant to the ELOC Agreement, as amended. During October 2023 and November 2023, we issued a total of 1,220,000 shares to Ionic in partial settlement of ELOC Advances. On November 18, 2023, we and Ionic entered into a letter agreement (the “November 2023 Letter Agreement”) which, among other things, amends the Subordinated Convertible Debenture, dated as of March 14, 2023, by and between Remark and Ionic (the “First 2023 Debenture”). The November 2023 Letter Agreement amends the First 2023 Debenture to include language that requires us to notify Ionic if we enter into any new debt agreement after November 18, 2023 or modify any debt agreement that existed at November 18, 2023. If Ionic determines that the terms of such new or modified agreements are preferable to the terms of the First 2023 Debenture, Ionic can give us written notice to amend, within five days, the terms of the First 2023 Debenture, excluding principal and interest, to give Ionic the benefit of such preferable terms. Failure to Maintain Continued Listing Standards On April 27, 2023, we received a written notice from the Nasdaq Listing Qualifications Department notifying us that, pursuant to Nasdaq Listing Rule 5550(b)(3), we are required to maintain a minimum of $500,000 in net income from continuing operations in the most recently completed fiscal year, or two of the last three fiscal years (the “Net Income Standard”). Since our 2022 Form 10-K reported net loss from continuing operations, and as of April 25, 2023, we did not meet the alternative continued listing standards (collectively, with the Net Income Standard, the “Continued Listing Standards”) under Nasdaq Listing Rule 5550(b) of a minimum stockholders' equity of $2.5 million or minimum market value of listed securities of $35 million, we no longer comply with the Continued Listing Standards. In accordance with Nasdaq Listing Rule 5810(c)(2)(A), on June 12, 2023 we submitted a plan to regain compliance with the Continued Listing Standards to the Nasdaq Listing Qualifications Department. On July 24, 2023, the Nasdaq Listing Qualifications Department notified us that it was granting us until October 24, 2023 (the “Extension Period”) to file a report with the SEC and Nasdaq stating that we have successfully executed our plan to regain compliance with the Continued Listing Standards and that we did in fact regain such compliance. We were not able to regain compliance with the Continued Listing Standards by October 24, 2023 and, on October 26, 2023, we received a staff determination letter from Nasdaq indicating that we did not regain compliance with the Continued Listing Standards and that, unless we request an appeal of Nasdaq’s determination, our common stock was subject to delisting. We appealed Nasdaq’s delisting determination to a Hearings Panel (the “Panel”) and were notified by Nasdaq that we have been granted a hearing with the Panel on February 1, 2024. Our common stock will continue to be listed and traded on the Nasdaq Capital Market pending a decision by the Panel.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation We prepared the accompanying unaudited Condensed Consolidated Balance Sheet as of September 30, 2023, with the audited Consolidated Balance Sheet amounts as of December 31, 2022 presented for comparative purposes, and the related unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss, the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Deficit nine months ended September 30, 2023 in accordance with the instructions for Form 10-Q. In compliance with those instructions, we have omitted certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP, though management believes the disclosures made herein are sufficient to ensure that the information presented is not misleading. Our results of operations and our cash flows as of the end of the interim periods reported herein do not necessarily indicate the results we may experience for the remainder of the year or for any other future period. Management believes that we have included all adjustments (including those of a normal, recurring nature) considered necessary to fairly present our unaudited Condensed Consolidated Balance Sheet and our unaudited Condensed Consolidated Statement of Stockholders’ Deficit, each as of September 30, 2023, as well as our unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss and Condensed Consolidated Statements of Cash Flows for all periods presented. You should read our unaudited condensed consolidated interim financial statements and footnotes in conjunction with our consolidated financial statements and footnotes included within the Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).
Consolidation	Consolidation We include all of our subsidiaries in our condensed consolidated financial statements, eliminating all significant intercompany balances and transactions during consolidation.
Use of Estimates	Use of Estimates We prepare our consolidated financial statements in conformity with GAAP. While preparing our financial statements, we make estimates and assumptions that affect amounts reported and disclosed in the consolidated financial statements and accompanying notes. Accordingly, actual results could differ from those estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, deferred cost of revenue, share-based compensation, deferred income taxes, and inventory reserve, among other items. The impact of the COVID-19 pandemic continues to unfold. As a result, many of our estimates and assumptions required increased judgment and carry a higher degree of variability and volatility. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.
Cash	Cash Our cash consists of funds held in bank accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). When reporting the fair values of our financial instruments, we prioritize those fair value measurements into one of three levels based on the nature of the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets and liabilities; Level 2: Valuations based on observable inputs that do not meet the criteria for Level 1, including quoted prices in inactive markets and observable market data for similar, but not identical instruments; and Level 3: Valuations based on unobservable inputs, which are based upon the best available information when external market data is limited or unavailable. The fair value hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not be available. We believe the reported carrying amounts for cash, marketable securities, receivables, prepaids and other current assets, accounts payable, accrued expense and other current liabilities, and short-term debt approximate their fair values because of the short-term nature of these financial instruments.
Foreign Currency Translation	Foreign Currency Translation We report all currency amounts in USD. Our overseas subsidiaries, however, maintain their books and records in their functional currencies, which are GBP in the United Kingdom (“U.K.”) and RMB in China. In general, when consolidating our subsidiaries with non-USD functional currencies, we translate the amounts of assets and liabilities into USD using the exchange rate on the balance sheet date, and the amounts of revenue and expense are translated at the average exchange rate prevailing during the period. The gains and losses resulting from translation of financial statement amounts into USD are recorded as a separate component of accumulated other comprehensive loss within stockholders’ deficit.
Revenue Recognition	Revenue Recognition AI-Based Products We generate revenue by developing AI-based products, including fully-integrated AI solutions which combine our proprietary technology with third-party hardware and software products to meet end-user specifications. Under one type of contract for our AI-based products, we provide a single, continuous service to clients who control the assets as we create them. Accordingly, we recognize the revenue over the period of time during which we provide the service. Under another type of contract, we have performance obligations to provide fully-integrated AI solutions to our customer and we recognize revenue at the point in time when each performance obligation is completed and delivered to, tested by and accepted by our customer. We recognize revenue when we transfer control of the promised goods or services to our customers, and we recognize an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. If there is uncertainty related to the timing of collections from our customer, which may be the case if our customer is not the ultimate end user of our goods, we consider this to be uncertainty of the customer’s ability and intention to pay us when consideration is due. Accordingly, we recognize revenue only when we have transferred control of the goods or services and collectability of consideration from the customer is probable. When customers pay us prior to when we satisfy our obligation to transfer control of promised goods or services, we record the amount that reflects the consideration to which we expect to be entitled as a contract liability until such time as we satisfy our performance obligation. For contracts under which we have not yet completed the performance obligation, deferred costs are recorded for any amounts incurred in advance of the performance obligation. For our contracts with customers, we generally extend short-term credit policies to our customers, typically up to one year for large-scale projects. We record the incremental costs of obtaining contracts as an expense when incurred. We offer extended warranties on our products for periods of one to three years. Revenue from these extended warranties is recognized on a straight-line basis over the warranty contract term. Other We generate revenue from other sources, such as from advertising and marketing services. We recognize the revenue from these contracts at the point in time when we transfer control of the good sold to the customer or when we deliver the promised promotional materials or media content. Substantially all of our contracts with customers that generate Other revenue are completed within one year or less.
Inventory	InventoryWe use the first-in first-out method to determine the cost of our inventory, then we report inventory at the lower of cost or net realizable value. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated sales forecasts.
Refundable Tax Credits	Refundable Tax CreditsWe charge the cost of our research and development efforts to operations as incurred. Our subsidiary in the United Kingdom is entitled to receive certain government assistance in the form of refundable research and development tax credits from taxation authorities, based on qualifying expenditures incurred during the fiscal year. The refundable credits are not dependent on our ongoing tax status or tax position and accordingly are not considered part of income taxes. We record refundable tax credits as a reduction of technology and development expense when we can reasonably estimate the amount and it is more likely than not that such amount will be received.
Internal Use Software	Internal Use Software We acquire or develop applications and other software that help us meet our internal needs with respect to operating our business. For such projects, planning cost and other costs related to the preliminary project stage, as well as costs incurred for post-implementation activities, are expensed as incurred. We capitalize costs incurred during the application development phase only when we believe it is probable the development will result in new or additional functionality. The types of costs capitalized during the application development phase include fees incurred with third parties for consulting, programming and other development activities performed to complete the software. We amortize our internal use software on a straight-line basis over an estimated useful life of three years. If we identify any internal use software to be abandoned, the cost less the accumulated amortization, if any, is recorded as amortization expense. Once we have fully amortized internal use software costs that we capitalized, we remove such amounts from their respective accounts.
Net Income (Loss) per Share	Net Income (Loss) per Share We calculate basic net income (loss) per share using the weighted-average number of common stock shares outstanding during the period. For the calculation of diluted net income (loss) per share, we give effect to all the shares of common stock that were outstanding during the period plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is anti-dilutive. Dilutive potential shares of common stock consist of incremental shares of common stock issuable upon exercise of stock options and warrants.
Segments	Segments Existing GAAP, which establishes a management approach to segment reporting, defines operating segments as components of an entity about which separate, discrete financial information is available for evaluation by the chief operating decision maker. We have identified our Chief Executive Officer as our chief operating decision maker, who reviews operating results to make decisions about allocating resources and assessing performance based upon only one operating segment.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06 (“ASU 2020-06”), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The ASU also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. With regard to our financial reporting, ASU 2020-06 will be effective January 1, 2024, and early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. We are currently evaluating what effect(s) the adoption of ASU 2020-06 may have on our consolidated financial statements, but we do not believe the impact of the ASU will be material to our financial position, results of operations and cash flows. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption. We have reviewed all accounting pronouncements recently issued by the FASB and the SEC. The authoritative pronouncements that we have already adopted did not have a material effect on our financial condition, results of operations, cash flows or reporting thereof, and except as otherwise noted above, we do not believe that any of the authoritative pronouncements that we have not yet adopted will have a material effect upon our financial condition, results of operations, cash flows or reporting thereof.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents

The following table, reported in USD, disaggregates our cash balances by currency denomination (in thousands):




	September 30, 2023		December 31, 2022
Cash denominated in:
USD	$	250	$	11
RMB	13		19
GBP	3		17
HKD	4		5
Total cash	$	270	$	52

Schedule of Exchange Rates

We used the exchange rates in the following table to translate amounts denominated in non-USD currencies as of and for the periods noted:


	2023	2022
Exchange rates at September 30th:
GBP:USD	1.220	1.113
RMB:USD	0.137	0.141
HKD:USD	0.128	0.127

Average exchange rate during the nine months ended September 30th:
RMB:USD	0.142	0.152
GBP:USD	1.244	1.259

REVENUE (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue by Major Category

The following table presents a disaggregation of our revenue by category of products and services (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
AI-based products and services, including amounts from China Business Partner in 2023 (See Note 15)	$	174	$	2,681	$	4,000	$	9,699
Other	9		131		176		338
Revenue	$	183	$	2,812	$	4,176	$	10,037

Schedule of Disaggregation of Revenue by Country

The following table presents a disaggregation of our revenue by country (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
China	$	174	$	2,746	$	4,014	$	9,815
United States and United Kingdom	9		66		162		222

Revenue	$	183	$	2,812	$	4,176	$	10,037

TRADE ACCOUNTS RECEIVABLE (Tables)

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

Schedule of Components of Prepaid Expense and Other Current Assets




	September 30, 2023		December 31, 2022
Gross accounts receivable balance	$	7,103	$	7,213
Allowance for bad debt	(4,060)		(4,122)
Accounts receivable, net	$	3,043	$	3,091

PREPAID EXPENSE AND OTHER CURRENT ASSETS (Tables)

9 Months Ended

Sep. 30, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expense and Other Current Assets

The following table presents the components of prepaid expense and other current assets (in thousands):




	September 30, 2023		December 31, 2022


Other receivables	2		23
Prepaid expense	547		1,144
Deposits	245		201

Other current assets	7		6
Total	$	801	$	1,374

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consist of the following (in thousands, except estimated lives):




	Estimated Life (Years)	September 30, 2023		December 31, 2022
Vehicles	3	$	153	153
Computers and equipment	3	1,193		$	1,170
Furniture and fixtures	3	42		42
Software	3	5,819		5,160
Leasehold improvements	3	206		204
Software development in progress		—		1,199
Total property, equipment and software		$	7,413	$	7,928
Less accumulated depreciation		(6,307)		(6,229)
Total property, equipment and software, net		$	1,106	$	1,699

ACCRUED EXPENSE AND OTHER CURRENT LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

Other Liabilities Disclosure [Abstract]

Schedule of Accrued Expense and Other Current Liabilities

The following table presents the components of Accrued expense and other current liabilities (in thousands):




	September 30, 2023		December 31, 2022
Accrued compensation and benefit-related expense	$	2,822	$	1,448
Accrued interest	633		769
Other accrued expense	3,302		2,393
Other payables	2,018		2,234
Operating lease liability - current	367		138
China Cash Bonuses (see Note 15)	14		32
Other current liabilities	197		208
Total	$	9,353	$	7,222

NOTES PAYABLE (PAST DUE) (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Notes Payable

The following table presents our notes payable (in thousands) as of:




	September 30, 2023		December 31, 2022
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)	$	16,307	$	14,418
Other notes payable	165		189
Notes payable, net of unamortized discount and debt issuance cost	$	16,472	$	14,607

OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC) (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Activity Related to All Obligations to Issue Shares

The following table shows the changes in our obligations to issue common stock (dollars in thousands):


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Obligations to Issue Common Stock
Balance at December 31, 2022	$	1,892	$	—	$	—	$	—	$	—	$	1,892
Establishment of new obligation to issue shares	—		4,109		332		249		10,483		15,173
Issuance of Shares	(3,138)		(94)		(294)		(227)		(5,167)		(8,920)
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Balance at September 30, 2023	$	—	$	4,673	$	—	$	—	$	4,511	$	9,184

Estimated Number of Shares Issuable
Balance at December 31, 2022	1,720,349		—		—		—		—		1,720,349
Establishment of new obligation to issue shares	—		3,669,228		300,000		200,715		11,326,803		15,496,746
Issuance of Shares	(2,230,814)		(97,000)		(300,000)		(200,715)		(5,343,762)		(8,172,291)
Change in estimated number of shares issuable	510,465		5,801,229		—		—		3,063,789		9,375,483
Balance at September 30, 2023	—		9,373,457		—		—		9,046,830		18,420,287

The following table shows the composition of finance cost associated with our obligations to issue common stock (dollars in thousands):


	2022 Debenture		2023 Debentures		Filing & Effectiveness Default		Letter Agreement		ELOC Advances		Total
Initial obligation in excess of purchase price	$	—	$	1,609	$	332	$	249	$	3,483	$	5,673
Change in measurement of liability	1,246		658		(38)		(22)		(805)		1,039
Total	$	1,246	$	2,267	$	294	$	227	$	2,678	$	6,712

STOCKHOLDERS' DEFICIT (Tables)

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Schedule of Share-based Payment Arrangement, Activity

The following table summarizes information related to our equity-classified stock warrant issuances as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	1,011,441	$	40.10	3.7	$	—
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	—	—
Outstanding at September 30, 2023	1,011,441	$	40.10	2.9	$	—

Schedule of Stock Option Activity Under Equity Incentive Plans

The following table summarizes activity under our equity incentive plans related to equity-classified stock option grants as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	1,626,631	$	30.31	5.5	$	1
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	(3,285)	46.75
Outstanding at September 30, 2023	1,623,346	$	30.28	5.0	$	—

Exercisable at December 31, 2022	1,549,681	31.41		5.3	$	1
Exercisable at September 30, 2023	1,601,649	30.79		4.6	$	—

The following table summarizes activity related to our liability-classified China Cash Bonuses as of and for the dates and periods noted:


	Shares	Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)




Outstanding at December 31, 2022	71,450	$	35.99	6.1	$	—
Granted	—	—
Exercised	—	—
Forfeited, cancelled or expired	—	—
Outstanding at September 30, 2023	71,450	$	35.99	5.4	$	—

Exercisable at December 31, 2022	68,450	36.97		6.1	$	—
Exercisable at September 30, 2023	71,450	35.99		5.4	$	—

Schedule of Change in Liability Balance Associated with China Cash Bonuses

The following table presents the change in the liability associated with our China Cash Bonuses included in Accrued expense and other current liabilities (in thousands):


	Nine Months Ended September 30,		Year Ended December 31,
	2023		2022
Balance at beginning of period	$	32	$	439
Share-based compensation expense related to China Cash Bonuses	(18)		(407)
Balance at end of period	$	14	$	32

Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount

The following table presents a breakdown of share-based compensation cost included in operating expense (in thousands):


	Nine Months Ended September 30,
	2023		2022
Stock options	$	167	$	1,525
China Cash Bonuses	(18)		(340)
Total	$	149	$	1,185

Schedule of Unrecognized Share-based Compensation Cost

The following table presents information regarding unrecognized share-based compensation cost associated with stock options and China Cash Bonuses:


			September 30, 2023
Unrecognized share-based compensation cost for non-vested awards (in thousands):
Stock options			31
China Cash Bonuses			—
Weighted-average years over which unrecognized share-based compensation expense will be recognized:
Stock options			1.4
China Cash Bonuses			0

ORGANIZATION AND BUSINESS (Details) $ in Thousands		9 Months Ended
ORGANIZATION AND BUSINESS (Details) $ in Thousands	Dec. 21, 2022	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Reverse common stock split ratio	0.1
Stockholders' deficit		$ 32,918	$ 28,429	$ 20,425	$ 14,690	$ 6,322	$ (31,034)
Net cash used in operating activities		9,100
Cash and cash equivalents		$ 270		$ 52
WFOE
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage by parent		100.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and cash equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Total cash	$ 270	$ 52
USD
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Total cash	250	11
RMB
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Total cash	13	19
GBP
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Total cash	3	17
HKD
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Total cash	$ 4	$ 5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates (Details)	Sep. 30, 2023	Sep. 30, 2022
GBP:USD
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate	1.220	1.113
GBP:USD \| Weighted Average
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate	1.244	1.259
RMB:USD
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate	0.137	0.141
RMB:USD \| Weighted Average
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate	0.142	0.152
HKD:USD
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate	0.128	0.127

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($) shares	Sep. 30, 2023 USD ($) segment shares	Dec. 31, 2022 USD ($) shares
Disaggregation of Revenue [Line Items]
Term of contract		1 year
Reserve for inventory \| $	$ 2.2	$ 2.2	$ 2.2
Tax credit \| $		$ 0.5
Number of operating segments \| segment		1
Warrant
Disaggregation of Revenue [Line Items]
Anti-dilutive securities (in shares) \| shares	1,011,441	1,011,441
Stock options
Disaggregation of Revenue [Line Items]
Shares of common stock outstanding (in shares) \| shares	1,623,346	1,623,346	1,626,631
Software
Disaggregation of Revenue [Line Items]
Estimate useful life (in years)	3 years	3 years
Other
Disaggregation of Revenue [Line Items]
Performance period (or less)		1 year
Minimum
Disaggregation of Revenue [Line Items]
Extended warranty period		1 year
Maximum
Disaggregation of Revenue [Line Items]
Extended warranty period		3 years

CONCENTRATION OF RISK (Details) - Customer Concentration Risk	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Customer A \| Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	28.00%	55.00%
Customer A \| Gross Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%		23.00%
Customer B \| Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%	23.00%
Customer B \| Gross Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%		16.00%
Customer C \| Gross Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage			10.00%

REVENUE - Schedule of Disaggregated by Major Category (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 183	$ 2,812	$ 4,176	$ 10,037
AI-based products and services, including amounts from China Business Partner in 2023 (See Note 15)
Disaggregation of Revenue [Line Items]
Revenue	174	2,681	4,000	9,699
Other
Disaggregation of Revenue [Line Items]
Revenue	$ 9	$ 131	$ 176	$ 338

REVENUE - Schedule of Disaggregation by Country (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 183	$ 2,812	$ 4,176	$ 10,037
China
Disaggregation of Revenue [Line Items]
Revenue	174	2,746	4,014	9,815
United States and United Kingdom
Disaggregation of Revenue [Line Items]
Revenue	$ 9	$ 66	$ 162	$ 222

REVENUE - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
REVENUE - Narrative (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue recognized on liability balances		$ 0	$ 0
Revenue recognized from performance obligations satisfied in previous periods		$ 0	$ 0
AI-Based Products
Disaggregation of Revenue [Line Items]
Revenue recognized on liability balances	$ 1,400,000

TRADE ACCOUNTS RECEIVABLE - Schedule of Components of Prepaid Expense and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Gross accounts receivable balance	$ 7,103	$ 7,213
Allowance for bad debt	(4,060)	(4,122)
Accounts receivable, net	$ 3,043	$ 3,091

TRADE ACCOUNTS RECEIVABLE - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Provision for doubtful accounts	$ 138	$ 2,278
China
Accounts, Notes, Loans and Financing Receivable [Line Items]
Provision for doubtful accounts			$ 2,800
Period past due			1 year
China \| AI-Based Products
Accounts, Notes, Loans and Financing Receivable [Line Items]
Trade receivables	$ 600		$ 1,100

DEFERRED COST OF REVENUE (Details) - USD ($)	3 Months Ended	9 Months Ended
DEFERRED COST OF REVENUE (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Deferred cost of revenue	$ 5,899,000	$ 5,899,000		$ 7,463,000
Revenue recognized on liability balances		0	$ 0
AI-Based Products
Disaggregation of Revenue [Line Items]
Deferred cost of revenue	1,200,000	$ 1,200,000
Revenue recognized on liability balances	$ 1,400,000

PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expense and Other Current Assets
Other receivables	$ 2	$ 23
Prepaid expense	547	1,144
Deposits	245	201
Other current assets	7	6
Total	801	$ 1,374
Impairments	$ 200

PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property, equipment and software	$ 7,413	$ 7,928
Less accumulated depreciation	(6,307)	(6,229)
Total property, equipment and software, net	$ 1,106	1,699
Vehicles
Property, Plant and Equipment [Line Items]
Estimated Life (Years)	3 years
Total property, equipment and software	$ 153	153
Computers and equipment
Property, Plant and Equipment [Line Items]
Estimated Life (Years)	3 years
Total property, equipment and software	$ 1,193	1,170
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Life (Years)	3 years
Total property, equipment and software	$ 42	42
Software
Property, Plant and Equipment [Line Items]
Estimated Life (Years)	3 years
Total property, equipment and software	$ 5,819	5,160
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated Life (Years)	3 years
Total property, equipment and software	$ 206	204
Software development in progress
Property, Plant and Equipment [Line Items]
Total property, equipment and software	$ 0	$ 1,199

PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization of software	$ 0.2	$ 0.2
Impairment	$ 0.2

ACCRUED EXPENSE AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Accrued compensation and benefit-related expense	$ 2,822	$ 1,448
Accrued interest	633	769
Other accrued expense	3,302	2,393
Other payables	2,018	2,234
Operating lease liability - current	367	138
China Cash Bonuses (see Note 15)	14	32
Other current liabilities	197	208
Total	$ 9,353	$ 7,222

NOTES PAYABLE (PAST DUE) - Schedule of Notes Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 14, 2023	Dec. 31, 2022	Jul. 11, 2022
Short-term Debt [Line Items]
Other notes payable	$ 165		$ 189
Notes payable, net of unamortized discount and debt issuance cost	16,472		14,607
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)
Short-term Debt [Line Items]
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)				$ 9,700
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022) \| Notes Payable
Short-term Debt [Line Items]
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)	$ 16,307	$ 14,400	$ 14,418

NOTES PAYABLE (PAST DUE) - Narrative (Details) - USD ($)			3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 14, 2023	Oct. 31, 2022	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 31, 2022	Jul. 11, 2022	Dec. 03, 2021
Debt Instrument [Line Items]
Amortization of debt issuance costs and discount						$ 0	$ 2,189,000
Interest expense			$ 949,000		$ 1,365,000	$ 3,351,000	$ 5,325,000
Short-term Note Payable to Private Lender
Debt Instrument [Line Items]
Note repayment of debt								$ 6,200,000
Debt, weighted average interest rate			6.20%			6.20%
Debt instrument, weighted average remaining term						4 years 6 months
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)
Debt Instrument [Line Items]
Principal balance of original mudrick loans										$ 9,700,000
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022) \| Short-term Note Payable to Private Lender
Debt Instrument [Line Items]
Principal balance of original mudrick loans	$ 14,400,000		$ 16,307,000			$ 16,307,000		14,418,000
Accrued interest on loan				$ 600,000
Interest expense				300,000
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022) \| Short-term Note Payable to Private Lender \| Accrued Expense and Other Current Liabilities
Debt Instrument [Line Items]
Accrued interest on loan								800,000
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022) \| Loans Payable
Debt Instrument [Line Items]
Principal balance of original mudrick loans											$ 30,000,000
Debt interest rate percentage	20.50%								18.50%		16.50%
Increase, interest rate	2.00%	20.50%
Upfront fee (in percent)											5.00%
Debt instrument, unamortized discount											$ 1,500,000
Additional closing cost											$ 1,100,000
Amortization of debt issuance costs and discount								$ 2,200,000
New Mudrick Note Purchase Agreement \| Mudrick Lenders
Debt Instrument [Line Items]
Principal balance of original mudrick loans	$ 16,300,000
Accrued interest on loan	1,100,000
Interest expense	$ 800,000			$ 800,000

OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC) - Narrative (Details)							3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 29, 2023 USD ($)	Sep. 15, 2023 USD ($)	Jun. 30, 2023 USD ($) shares	Mar. 14, 2023 USD ($) price day debenture $ / shares shares	Jan. 05, 2023 USD ($) day $ / shares	Oct. 06, 2022 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2023 USD ($) shares
Debt Instrument [Line Items]
Obligations to issue common stock							$ 9,184,000	$ 9,184,000	$ 1,892,000
Common stock issued pursuant to agreements with Ionic (Note 11)							2,497,000	8,918,000
Letter Agreement
Debt Instrument [Line Items]
Obligations to issue common stock			$ 200,000
Establishment of new obligation to issue shares (in shares) \| shares			200,715
2022 Debenture
Debt Instrument [Line Items]
Obligations to issue common stock									$ 1,900,000
2022 Debenture \| Forecast
Debt Instrument [Line Items]
Obligations to issue common stock										$ 3,100,000
Additional shares to issue (in shares) \| shares										2,230,814
2023 Debentures
Debt Instrument [Line Items]
Obligations to issue common stock							$ 4,700,000	$ 4,700,000
Additional shares to issue (in shares) \| shares							9,373,457	9,373,457
2023 Debentures \| First Debenture
Debt Instrument [Line Items]
Obligations to issue common stock				$ 4,100,000
Additional shares to issue (in shares) \| shares				3,669,228
2023 Debentures \| Second Debenture
Debt Instrument [Line Items]
Obligations to issue common stock				$ 4,100,000
Additional shares to issue (in shares) \| shares				3,669,228
ELOC Purchase Agreement \| First Debenture
Debt Instrument [Line Items]
Establishment of new obligation to issue shares								$ 10,500,000
Establishment of new obligation to issue shares (in shares) \| shares								11,326,803
ELOC Purchase Agreement \| Second Debenture
Debt Instrument [Line Items]
Common stock issuance upon note payable conversion (in shares) \| shares								5,343,762
Common stock issued pursuant to agreements with Ionic (Note 11)								$ 5,200,000
ELOC Purchase Agreement \| Third Debenture
Debt Instrument [Line Items]
Additional shares to issue (in shares) \| shares							9,046,830	9,046,830
Aggregate fair value of obligation							$ 4,500,000	$ 4,500,000
Ionic
Debt Instrument [Line Items]
Additional shares to issue (in shares) \| shares							18,420,287	18,420,287	1,720,349
Settlement shares (in shares) \| shares						3,129,668			898,854
Establishment of new obligation to issue shares								$ 15,173,000
Establishment of new obligation to issue shares (in shares) \| shares								15,496,746
Common stock issuance upon note payable conversion (in shares) \| shares								8,172,291
Common stock issued pursuant to agreements with Ionic (Note 11)								$ 8,920,000
Aggregate fair value of obligation							$ 9,184,000	$ 9,184,000	$ 1,892,000
Ionic \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Sale of stock, amount authorized in transaction						$ 50,000,000
Stock purchase obligation, period of purchase						36 months
Cash received on sale of shares						$ 3,000,000
Sale of stock, additional number of shares issued in percentage						2.50%
Required minimum closing trading price (in usd per share) \| $ / shares						$ 0.20
Stockholder approval, outstanding percentage of common stock percentage						19.99%
Payable termination fee						$ 500,000
Ionic \| Maximum \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Sale of stock, purchase price, percentage						90.00%
Ionic \| Minimum \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Sale of stock, amount authorized in transaction						$ 25,000,000
Sale of stock, purchase price, percentage						80.00%
Ionic \| Letter Agreement
Debt Instrument [Line Items]
Initial liability amount						$ 3,600,000
Additional shares to issue (in shares) \| shares							0	0	0
Establishment of new obligation to issue shares								$ 249,000
Establishment of new obligation to issue shares (in shares) \| shares								200,715
Common stock issuance upon note payable conversion (in shares) \| shares								200,715
Common stock issued pursuant to agreements with Ionic (Note 11)								$ 227,000
Aggregate fair value of obligation							$ 0	$ 0	$ 0
Ionic \| Letter Agreement \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Shares required to issue (in shares) \| shares				150,000
Shares required to issue, period				2 days
Liquidated damages percentage				2.00%
Liquidated damages period				30 days
Registration rights agreement, number of shares issued in transaction \| shares			300,000
Registration rights agreement, liabilities			$ 300,000
Ionic \| Letter Agreement \| Maximum \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Effective declaration period				120 days
Ionic \| Letter Agreement \| Minimum \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Filing period \| day				15
Effective declaration period				90 days
Ionic \| Letter Agreement \| Convertible Subordinated Debt
Debt Instrument [Line Items]
Principal balance of original mudrick loans				$ 2,800,000		2,800,000
Repurchase amount				$ 2,500,000		$ 2,500,000
Number of debentures \| debenture				2
Debt interest rate percentage				10.00%
Interest guaranteed period				2 years
Increase, interest rate				15.00%
Suspension from trading or delisting, trading days \| day				3
Covenant, conversion period				181 days
Number of volume-weighted average prices \| price				2
Conversion price (in usd per share) \| $ / shares				$ 1.40
Conversion percentage, bankruptcy multiplier				120.00%
Beneficial ownership limitation percentage				4.99%
Ionic \| Letter Agreement \| Convertible Subordinated Debt \| Maximum
Debt Instrument [Line Items]
Debt conversion percentage				80.00%
Ionic \| Letter Agreement \| Convertible Subordinated Debt \| Minimum
Debt Instrument [Line Items]
Debt conversion percentage				70.00%
Conversion price (in usd per share) \| $ / shares				$ 0.20
Ionic \| Letter Agreement \| Convertible Subordinated Debt \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Principal balance of original mudrick loans				$ 3,300,000
Ionic \| 2022 Debenture
Debt Instrument [Line Items]
Additional shares to issue (in shares) \| shares							0	0	1,720,349
Establishment of new obligation to issue shares								$ 0
Establishment of new obligation to issue shares (in shares) \| shares								0
Common stock issuance upon note payable conversion (in shares) \| shares								2,230,814
Common stock issued pursuant to agreements with Ionic (Note 11)								$ 3,138,000
Aggregate fair value of obligation							$ 0	$ 0	$ 1,892,000
Ionic \| First Debenture Purchase Agreement \| Convertible Subordinated Debt \| First Debenture
Debt Instrument [Line Items]
Principal balance of original mudrick loans				1,700,000
Repurchase amount				1,500,000
Ionic \| Second Debenture Purchase Agreement \| Convertible Subordinated Debt \| Second Debenture
Debt Instrument [Line Items]
Principal balance of original mudrick loans				1,100,000
Repurchase amount				$ 1,000,000
Ionic \| 2023 Debentures
Debt Instrument [Line Items]
Additional shares to issue (in shares) \| shares							9,373,457	9,373,457	0
Establishment of new obligation to issue shares								$ 4,109,000
Establishment of new obligation to issue shares (in shares) \| shares								3,669,228
Common stock issuance upon note payable conversion (in shares) \| shares								97,000
Common stock issued pursuant to agreements with Ionic (Note 11)								$ 94,000
Aggregate fair value of obligation							$ 4,673,000	4,673,000	$ 0
Ionic \| Debenture Purchase Agreement Amendment \| Convertible Subordinated Debt
Debt Instrument [Line Items]
Beneficial ownership limitation percentage						4.99%
Ionic \| Letter Agreement With Ionic \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Suspension from trading or delisting, trading days \| day					10
Debt conversion percentage		80.00%
Cash received on sale of shares					$ 500,000
Minimum trading amount					$ 13,900,000
Sale of stock, maximum trading amount		$ 20,000,000
Commitment fee	$ 3,800,000
Ionic \| Letter Agreement With Ionic \| Maximum \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Debt conversion percentage					80.00%
Conversion price (in usd per share) \| $ / shares					$ 0.25
Commitment fee		3,000,000
Ionic \| Letter Agreement With Ionic \| Minimum \| ELOC Purchase Agreement
Debt Instrument [Line Items]
Debt conversion percentage					70.00%
Commitment fee		$ 500,000
Ionic \| ELOC Advances
Debt Instrument [Line Items]
Principal balance of original mudrick loans							$ 7,000,000	$ 7,000,000
Additional shares to issue (in shares) \| shares							9,046,830	9,046,830	0
Establishment of new obligation to issue shares								$ 10,483,000
Establishment of new obligation to issue shares (in shares) \| shares								11,326,803
Common stock issuance upon note payable conversion (in shares) \| shares								5,343,762
Common stock issued pursuant to agreements with Ionic (Note 11)								$ 5,167,000
Aggregate fair value of obligation							$ 4,511,000	$ 4,511,000	$ 0

OBLIGATIONS TO ISSUE COMMON STOCK (TRANSACTIONS WITH IONIC) - Schedule of Activity Related to All Obligations to Issue Shares (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Obligations to Issue Common Stock
Issuance of Shares		$ (2,497)	$ (8,918)
Convertible Debenture Rollforward [Roll Forward]
Total			6,712	$ 0
Ionic
Obligations to Issue Common Stock
Beginning balance of convertible debenture, current			1,892
Establishment of new obligation to issue shares			15,173
Issuance of Shares			(8,920)
Change in measurement of liability			1,039
Ending balance of convertible debenture, current		$ 9,184	$ 9,184
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Beginning (in shares)			1,720,349
Establishment of new obligation to issue shares (in shares)			15,496,746
Issuance of Shares (in shares)			(8,172,291)
Change in estimated number of shares issuable (in shares)			9,375,483
Estimated Number of Shares Issuable, Ending (in shares)		18,420,287	18,420,287
Initial obligation in excess of purchase price			$ 5,673
Change in measurement of liability			1,039
Total			6,712
2022 Debenture \| Ionic
Obligations to Issue Common Stock
Beginning balance of convertible debenture, current			1,892
Establishment of new obligation to issue shares			0
Issuance of Shares			(3,138)
Change in measurement of liability			1,246
Ending balance of convertible debenture, current		$ 0	$ 0
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Beginning (in shares)			1,720,349
Establishment of new obligation to issue shares (in shares)			0
Issuance of Shares (in shares)			(2,230,814)
Change in estimated number of shares issuable (in shares)			510,465
Estimated Number of Shares Issuable, Ending (in shares)		0	0
Initial obligation in excess of purchase price			$ 0
Change in measurement of liability			1,246
Total			$ 1,246
2023 Debentures
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Ending (in shares)		9,373,457	9,373,457
2023 Debentures \| Ionic
Obligations to Issue Common Stock
Beginning balance of convertible debenture, current			$ 0
Establishment of new obligation to issue shares			4,109
Issuance of Shares			(94)
Change in measurement of liability			658
Ending balance of convertible debenture, current		$ 4,673	$ 4,673
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Beginning (in shares)			0
Establishment of new obligation to issue shares (in shares)			3,669,228
Issuance of Shares (in shares)			(97,000)
Change in estimated number of shares issuable (in shares)			5,801,229
Estimated Number of Shares Issuable, Ending (in shares)		9,373,457	9,373,457
Initial obligation in excess of purchase price			$ 1,609
Change in measurement of liability			658
Total			2,267
Filing & Effectiveness Default \| Ionic
Obligations to Issue Common Stock
Beginning balance of convertible debenture, current			0
Establishment of new obligation to issue shares			332
Issuance of Shares			(294)
Change in measurement of liability			(38)
Ending balance of convertible debenture, current		$ 0	$ 0
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Beginning (in shares)			0
Establishment of new obligation to issue shares (in shares)			300,000
Issuance of Shares (in shares)			(300,000)
Change in estimated number of shares issuable (in shares)			0
Estimated Number of Shares Issuable, Ending (in shares)		0	0
Initial obligation in excess of purchase price			$ 332
Change in measurement of liability			(38)
Total			294
Letter Agreement
Convertible Debenture Rollforward [Roll Forward]
Establishment of new obligation to issue shares (in shares)	200,715
Letter Agreement \| Ionic
Obligations to Issue Common Stock
Beginning balance of convertible debenture, current			0
Establishment of new obligation to issue shares			249
Issuance of Shares			(227)
Change in measurement of liability			(22)
Ending balance of convertible debenture, current		$ 0	$ 0
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Beginning (in shares)			0
Establishment of new obligation to issue shares (in shares)			200,715
Issuance of Shares (in shares)			(200,715)
Change in estimated number of shares issuable (in shares)			0
Estimated Number of Shares Issuable, Ending (in shares)		0	0
Initial obligation in excess of purchase price			$ 249
Change in measurement of liability			(22)
Total			227
ELOC Advances \| Ionic
Obligations to Issue Common Stock
Beginning balance of convertible debenture, current			0
Establishment of new obligation to issue shares			10,483
Issuance of Shares			(5,167)
Change in measurement of liability			(805)
Ending balance of convertible debenture, current		$ 4,511	$ 4,511
Convertible Debenture Rollforward [Roll Forward]
Estimated Number of Shares Issuable, Beginning (in shares)			0
Establishment of new obligation to issue shares (in shares)			11,326,803
Issuance of Shares (in shares)			(5,343,762)
Change in estimated number of shares issuable (in shares)			3,063,789
Estimated Number of Shares Issuable, Ending (in shares)		9,046,830	9,046,830
Initial obligation in excess of purchase price			$ 3,483
Change in measurement of liability			(805)
Total			$ 2,678

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Millions	Dec. 31, 2022	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Accrued penalty		$ 1.0
Payment of registration rights agreement penalty	$ 0.2
Unpaid amount included in other accrued expense		$ 0.8

STOCKHOLDERS' DEFICIT - Schedule of Share-based Payment Arrangement, Activity (Details) - Warrant - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Shares
Outstanding at beginning of period (in share)	1,011,441
Granted (in shares)	0
Exercised (in shares)	0
Forfeited, cancelled or expired (in shares)	0
Outstanding at end of period (in shares)	1,011,441	1,011,441
Weighted Average Exercise Price Per Share
Outstanding at beginning of period (in dollars per share)	$ 40.10
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited, cancelled or expired (in dollars per share)	0
Outstanding at end of period (in dollars per share)	$ 40.10	$ 40.10
Weighted-Average Remaining Contractual Term
Outstanding (term)	2 years 10 months 24 days	3 years 8 months 12 days
Aggregate Intrinsic Value (in thousands)
Outstanding	$ 0	$ 0

STOCKHOLDERS' DEFICIT - Narrative (Details)	9 Months Ended
STOCKHOLDERS' DEFICIT - Narrative (Details)	Sep. 30, 2023
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option award expiration period	10 years

STOCKHOLDERS' DEFICIT - Schedule of Stock Option Activity Under Equity Incentive Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Stock options
Shares
Outstanding at beginning of period (in shares)	1,626,631
Granted (in shares)	0
Exercised (in shares)	0
Forfeited, cancelled or expired (in shares)	(3,285)
Outstanding at end of period (in shares)	1,623,346	1,626,631
Options exercisable (in shares)	1,601,649	1,549,681
Weighted Average Exercise Price Per Share
Outstanding at beginning of period (in dollars per share)	$ 30.31
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited, cancelled or expired (in dollars per share)	46.75
Outstanding at end of period (in dollars per share)	30.28	$ 30.31
Options exercisable (in dollars per share)	$ 30.79	$ 31.41
Weighted-Average Remaining Contractual Term
Outstanding (term)	5 years	5 years 6 months
Options exercisable (term)	4 years 7 months 6 days	5 years 3 months 18 days
Aggregate Intrinsic Value (in thousands)
Outstanding	$ 0	$ 1
Options exercisable	$ 0	$ 1
China Cash Bonuses
Shares
Outstanding at beginning of period (in shares)	71,450
Granted (in shares)	0
Exercised (in shares)	0
Forfeited, cancelled or expired (in shares)	0
Outstanding at end of period (in shares)	71,450	71,450
Options exercisable (in shares)	71,450	68,450
Weighted Average Exercise Price Per Share
Outstanding at beginning of period (in dollars per share)	$ 35.99
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited, cancelled or expired (in dollars per share)	0
Outstanding at end of period (in dollars per share)	35.99	$ 35.99
Options exercisable (in dollars per share)	$ 35.99	$ 36.97
Weighted-Average Remaining Contractual Term
Outstanding (term)	5 years 4 months 24 days	6 years 1 month 6 days
Options exercisable (term)	5 years 4 months 24 days	6 years 1 month 6 days
Aggregate Intrinsic Value (in thousands)
Outstanding	$ 0	$ 0
Options exercisable	$ 0	$ 0

STOCKHOLDERS' DEFICIT - Schedule of Change in Liability Balance Associated with China Cash Bonuses (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Share-based Payment Award Liability [Roll Forward]
Balance at beginning of period	$ 32
Share-based compensation expense related to China Cash Bonuses	149	$ 1,185
Balance at end of period	14		$ 32
China Cash Bonuses
Share-based Payment Award Liability [Roll Forward]
Balance at beginning of period	32	439	439
Share-based compensation expense related to China Cash Bonuses	(18)	$ (340)	(407)
Balance at end of period	$ 14		$ 32

STOCKHOLDERS' DEFICIT - Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 149	$ 1,185
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	167	1,525
China Cash Bonuses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ (18)	$ (340)	$ (407)

STOCKHOLDERS' DEFICIT - Schedule of Unrecognized Share-based Compensation Cost (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation cost for non-vested awards	$ 31
Weighted-average years over which unrecognized share-based compensation expense will be recognized	1 year 4 months 24 days
China Cash Bonuses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation cost for non-vested awards	$ 0
Weighted-average years over which unrecognized share-based compensation expense will be recognized	0 years

RELATED PARTY TRANSACTIONS (Details) $ in Millions	Sep. 30, 2023 USD ($)
Management \| Advances To Senior Management For Operating Expenses
Related Party Transaction [Line Items]
Accounts payable	$ 1.0

CHINA BUSINESS PARTNER (Details) - USD ($) $ in Thousands	9 Months Ended
CHINA BUSINESS PARTNER (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Trade accounts receivable, net	$ 3,043		$ 3,091
China Branding Group Limited
Related Party Transaction [Line Items]
Revenues	100	$ 5,300
China Branding Group Limited \| VIE
Related Party Transaction [Line Items]
Trade accounts receivable, net	$ 700		$ 700

SUBSEQUENT EVENTS (Details) - Ionic - USD ($) $ in Millions	1 Months Ended
SUBSEQUENT EVENTS (Details) - Ionic - USD ($) $ in Millions	Nov. 20, 2023	Oct. 31, 2023	Sep. 30, 2023
Final Settlement, 2022 Debenture \| Subsequent Event
Subsequent Event [Line Items]
Number of shares issued in transaction (in shares)	1,220,000	1,220,000
ELOC Advances
Subsequent Event [Line Items]
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)			$ 7.0
ELOC Advances \| Subsequent Event
Subsequent Event [Line Items]
Principal balance of New Mudrick Notes (September 30, 2023) and Original Mudrick Loans (December 31, 2022)	$ 0.6